EXHIBIT 1







EXHIBIT A
Curriculum Vitae

Erik Richard Dubberke, MD, MSPH

1

CURRICULUM VITAE

Erik Richard Dubberke, MD, MSPH, FSHEA, FIDSA

DATE: December 26, 2018

PERSONAL INFORMATION

Date of Birth: February 10, 1973

Place of Birth: Chicago, IL

CITIZENSHIP U.S.A

ADDRESS Office: 4523 Clayton Ave. Box 8051

Saint Louis, MO 63110

(314) 454-8296 (work)

(314) 483-7099 (pager)

(314) 454-5392 (fax)

edubberk@wustl.edu

Home: 1419 Lindgate Dr.

St. Louis, MO 63122

PRESENT POSITION Professor of Medicine

Infectious Diseases Division

Department of Medicine

Washington University School of Medicine

EDUCATION

1991-1995 B.A. Augustana College, Rock Island, IL: Major-biology, Minor-biochemistry

1995-1999 M.D. University of Illinois at Chicago College of Medicine, Rockford Campus, 

Rockford, IL: Medicine

2003-2008 M.S.P.H St. Louis University School of Public Health, St. Louis, MO: Epidemiology

POSTGRADUATE TRAINING

1999-2000 Medicine Internship

Washington University School of Medicine, Barnes-Jewish Hospital, St. Louis, 

MO

2000-2002 Medicine Residency

Washington University School of Medicine, Barnes-Jewish Hospital, St. Louis, 

MO

2002-2005 Infectious Diseases Fellowship

Washington University School of Medicine, Barnes-Jewish Hospital, St. Louis, 

MO

ADDITIONAL TRAINING

Fall 2003 Designing Outcomes and Clinical Research Course

Department of Internal Medicine

Washington University School of Medicine

Spring 2004 Strategies for Successful Grant Proposals

Academic Publishing Department

Washington University School of Medicine

Spring 2005 SHEA/CDC Hospital Epidemiology Training Course
Curriculum Vitae

Erik Richard Dubberke, MD, MSPH

2

Summer 2006 Studied in laboratory of Dr. Dale Gerding, Professor of Medicine, Loyola 

University School of Medicine, Associate Chief of Staff, Hines VA Hospital,

learning C. difficile culturing and typing techniques

2005-2007 K30 Mentored Training Program in Clinical Research: mentor: Bradley Evanoff, 

MD

ACADEMIC POSITIONS:

2005-2007 Instructor, Department of Medicine, Washington University School of Medicine

2007-2013 Assistant Professor, Department of Medicine, Washington University School of 

Medicine

2013-2018 Associate Professor, Department of Medicine, Washington University School of 

Medicine

2018 Professor, Department of Medicine, Washington University School of Medicine

UNIVERSITY APPOINTMENTS AND COMMITTEES

2001-Present Member, Infection Control Committee, Barnes-Jewish Hospital

2003-2005 Infectious Diseases Fellowship Program Evaluation Committee, Washington 

University School of Medicine

2004-Present Member, Antibiotic Utilization Review Subcommittee, Barnes-Jewish 

Hospital

2005-Present Research Associate Member in the Translational and Clinical Research Program, 

Siteman Cancer Center

2007-Present Intern Selection Committee, Department of Medicine, Washington University 

School of Medicine

2007-Present Member, Washington University Institute for Clinical and Translational Sciences

2009-Present Full Member, Washington University Digestive Diseases Research Core Center

2011-Present Transplant Steering Committee, Barnes-Jewish Hospital

MEDICAL LICENSURE AND CERTIFICATION

2000 National Board of Medical Examiners [steps 1, 2 and 3 passed]

2001-present State of Missouri Medical License

2002, 2012 Board Certified, American Board of Internal Medicine, Internal Medicine 

[recertification in 2022]

2004, 2014 Board Certified, American Board of Internal Medicine, Infectious Diseases 

[recertification in 2024]

HONORS AND AWARDS

Undergraduate:

1992 Aristiae Freshman Honor Society

1992-1995 Dean’s List

1991-1995 Presidential Scholarship

1995 Phi Beta Kappa

1995 Summa cum laude

Graduate School:

2008 Golden Key National Honor Society

2008 Alumni Association Academic Achievement Award

Medical School:

1996 American Society of Clinical Pathologists’ Award for Academic Excellence and 

Achievement

1998-1999 Illinois General Assembly Scholarship

1998 Alpha Omega Alpha
Curriculum Vitae

Erik Richard Dubberke, MD, MSPH

3

1999 Outstanding Performance on Surgery Award

1999 James Scholar Award for Outstanding Research Project 

1999 Dr. Charles Williamson Award for Excellence in Medicine

1999 Graduated with Honors (awarded to top two graduates)

Residency:

1999 Barnes-Jewish Hospital Caring Spirit Award

Fellowship:

2004-2006 Loan Repayment Program, National Institutes of Health

2004 Travel Grant Award, Infectious Diseases Society of America

2005 Trainee Award, Society for Healthcare Epidemiology of America

2005 Travel Grant Award, Infectious Diseases Society of America

Faculty:

2007-2008 Loan Repayment Program, National Institutes of Health

2008-2009 Loan Repayment Program, National Institutes of Health

2009-2011 Loan Repayment Program, National Institutes of Health

2009 Clinical Infectious Diseases Award for Outstanding Review

2012 Rochester General Hospital Association Teaching Fellowship

2013 Fellow, Society for Healthcare Epidemiology of America

2015 Fellow, Infectious Diseases Society of America

2015-Present Best Doctors in America 

2015-Present Highly Cited Researcher, Web of Science, Clarivate Analytics

2016 Society for Healthcare Epidemiology of America Mid-Career Scholar Award

EDITORIAL RESPONSIBILITIES

Ad hoc

Advances in Hematology (2010)

American College of Physicians Physician’s Information and Education 

Resource (PIER) (2007-2009)

American Family Physician (2012)

American Journal of Infection Control (2005, 2012-2015)

American Journal of Transplantation (2007-2010)

American Society of Hematology Education Program Book (2004)

Anaerobe (2013, 2018)

Annals of Internal Medicine (2011-2012)

Bone Marrow Transplantation (2009)

Clinical Gastroenterology and Hepatology (2011)

Clinical Infectious Diseases (2007-2018)

Clinical Microbiology and Infection (2009)

Emerging Infectious Diseases (2011)

European Journal of Clinical Microbiology and Infectious Diseases (2012)

Expert Review of Anti-Infective Therapy (2013)

Infection Control and Hospital Epidemiology (2007-2018)

Intensive Care Medicine (2007)

JAMA Internal Medicine (2015)

Journal of the American Medical Association (2008-2017)

Journal of Clinical Microbiology (2008-2014)

Journal of Infectious Diseases (2012)

Lancet ID (2013-2016)

Leukemia and Lymphoma (2008)

Mayo Clinic Proceedings (2014)
Curriculum Vitae

Erik Richard Dubberke, MD, MSPH

4

New England Journal of Medicine (2012-2016)

Pharmacotherapy (2007)

Pharmacy and Therapeutics (2006)

Transplant Infectious Disease (2010-2012)

Vaccine (2015)

Editorial Board

Infection Control and Hospital Epidemiology (2011-2018)

Peer Reviewer

UpToDate, C. difficile infection (2018-present)

NATIONAL and INTERNATIONAL SCIENTIFIC PANELS

2010 Department of Veterans Affairs, Cooperative Studies Program, peer reviewer

2011 Study section ZRG1 PSE B (90)A, SRO Fungai Chanetsa, PhD, peer reviewer

2012 Health Protection Agency, United Kingdom, SRDF 2011/12 – SRDF 027, peer 

reviewer

2012-2014 Chimerix, protocol CMX001-350, central adjudication committee member

2014 Pfizer, Advancing Science through Pfizer-Investigator Research Exchange 

(ASPIRE), peer reviewer

2016 University of Western Australia, Doctor of Philosophy candidate Deirdre Anne 

Collins, Examiner

2015-Present Department of Veterans Affairs, Cooperative Studies Program, Optimal 

Treatment for Recurrent Clostridium difficile Infection, CSP #596, Data 

Monitoring Committee member

2017-Present American Gastroenterology Association, FMT National Registry, Observational 

Study Monitoring Board member

2018-Present Combatting Bacterial Resistance in Europe - Clostridium Difficile Infections 

(COMBACTE-CDI), Scientific Advisory Board

2018-2019 11th International Conference on the Molecular Biology and Pathogenesis of the 

Clostridia (ClostPath 11), International Scientific Committee member 

2018 Medical College of Wisconsin Advancing a Healthier Wisconsin Endowment, 

peer reviewer

2018-2019 C. diff Foundation, 7th Annual International C. diff Conference and Health Expo, 

co-chair

PROFESSIONAL SOCIETIES AND ORGANIZATIONS

2002-Present Member, Infectious Diseases Society of America (IDSA)

 2012-Present: Clinical Practice Guidelines for Clostridium difficile 

Infection Update Committee

 2015: Fellow, IDSA

2004-Present Member, Comprehensive Cancer Centers Infection Control Group

2005-Present Member, Society for Healthcare Epidemiology of America (SHEA)

 2007, 2013: SHEA Hospital Acquired Infection Compendium Taskforce

 2007-2011: Annual Meeting Planning Committee

 2007: Annual Meeting, Moderator, Clostridium difficile oral abstracts

 2008-2009; 2010-2011: Chair, Annual Meeting Awards Committee

 2009: SHEA representative, Key Informant, AHRQ Minnesota Evidencebased Practice Center, C. difficile review

 2010 Decennial Meeting, Moderator, C. difficile oral abstracts

 2011-2014: SHEA Awards Committee, Chair

 2011-2013: SHEA Education Committee
Curriculum Vitae

Erik Richard Dubberke, MD, MSPH

5

 2012: ID Week planning committee, abstract reviewer, and moderator

 2013: ID Week moderator

 2013: SHEA Member Spotlight, November 2013

 2013: Fellow of SHEA

 2014: ID Week moderator

 2014: ID Week abstract reviewer

 2014: ID Week poster rounds group leader: Clostridium difficile, 

Healthcare Environment

 2014-2016: Chair, SHEA Journal Club

 2015: ID Week abstract reviewer

 2015: ID Week poster rounds group leader: Clostridium difficile

 2017: SHEA representative at the XVIII Congress of the Asociacion 

Panamericana de Infectologia

 2019: Co-Chair, Prevention CHKC CME course

2005-Present Member, American Society of Transplantation

 2009 Senior author, Infectious Diseases Guidelines 2

nd edition, 

Clostridium difficile

 2009 Annual Meeting Abstract Reviewer

 2010 Annual Meeting Abstract Reviewer

 2012 Senior author, Infectious Diseases Guidelines 3

rd edition, 

Clostridium difficile

2006-Present Member, Site-PI, Mycosis Study Group

2013-Present Member, European Society for Clinical Microbiology and Infectious Diseases

 2015: ECCMID abstract reviewer

 2016: ECCMID abstract reviewer

 2017: ECCMID abstract reviewer

 2018: ECCMID abstract reviewer

 2018-Present: C. difficile study group member

2014-Present International Clostridium difficile Symposium Planning Committee

INVITED PROFESSORSHIPS AND LECTURESHIPS

June 2005 Infectious Diseases: Common Problems, Practical Answers, St. Louis, MO –

Recurrent C. difficile-associated Disease

Sept 2005 Missouri Baptist Medical Center, Medicine Grand Rounds, St. Louis, MO – C. 

difficile-associated Disease: The Best Treatment is Prevention

Nov 2005 What’s New, What’s Hot, and What’s Back in Infections Diseases, St. Louis, MO 

– Infective Endocarditis

Nov 2005 Galaxy of Gastroenterology IV, St. Louis, MO – Treatment of C. difficileassociated disease

Jan 2006 Cape Girardeau Medical Society 9th Annual Infectious Diseases Update - C. 

difficile-associated disease: the Good, the Bad, and the Messy

Feb 2006 St. Louis Regional Association for Professionals in Infection Control (APIC) 

Conference – Prevention of C. difficile-Associated Disease

Mar 2006 Gastroenterology Symposium, St. Mary’s Medical Center, Evansville, IN –

Infections of the Gastrointestinal Tract

Apr 2006 Boone County Medical Center, Columbia MO – Clostridium difficile Colitis

Sept 2006 Medicine Grand Rounds, St. Luke’s Medical Center, Chesterfield, MO –

Difficulties with Clostridium difficile

Oct 2006 Critical Care Grand Rounds, St. John’s Medical Center, Creve Coeur, MO –

Trends, Diagnosis, and Treatment of Clostridium difficile

Oct 2006 Medical Staff Symposium, Monongahela Valley Hospital, Monongahela, PA –

Clostridium difficile Colitis
Curriculum Vitae

Erik Richard Dubberke, MD, MSPH

6

Nov 2006 Central Illinois Regional Association for Professionals in Infection Control (APIC) 

conference, Bloomington, IL – Preventing Clostridium difficile

Nov 2006 Medicine Grand Rounds, Deaconess Hospital, Evansville, IN - Reexamining 

Treatment Practices for Complicated C. difficile-Associated Disease

Feb 2007 Infectious Diseases Update, Boone County Hospital, Columbia, MO-Clostridium 

difficile Colitis Review

Apr 2007 American College of Physicians Annual Meeting, Satellite Symposium, San 

Diego, CA – The Changing Epidemiology of Clostridium difficile and Identification 

of Toxin Variant Strains

Sept 2007 Critical Care Grand Rounds, St. John’s Medical Center, Creve Coeur, MO –

UPDATE: Trends, Diagnosis, and Treatment of Clostridium difficile

Sept 2007 Central Ohio Regional Association for Professionals in Infection Control (APIC) 

conference, Blacklick, OH - Reexamining Treatment Practices for Complicated C. 

difficile-Associated Disease

Sept 2007 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 

47th Annual meeting, Chicago, IL – Varicella Zoster Virus on a Bone Marrow 

Transplant Unit

March 2008 Medicine Grand Rounds, Barnes-Jewish Hospital, Washington University School 

of Medicine, St. Louis, MO – Clostridium difficile Infections: The Best Treatment 

is Prevention

April 2008 Society for Healthcare Epidemiology of America Annual Meeting, Orlando, FL –

Meet the Consultant: Clostridium difficile Infection

April 2008 Medicine Grand Rounds, University of South Dakota, Sanford School of 

Medicine, Sioux Falls, SD – Difficulties with Clostridium difficile

May 2008 Association for Professionals in Infection Control (APIC) Webinar Series –

Clostridium difficile: Tracking Transmission

June 2008 Association for Professionals in Infection Control (APIC) Annual Meeting, 

Satellite Symposium, Denver, CO – Clostridium difficile Infection: Surveillance 

and Diagnosis

Nov 2008 Clostridium difficile: A Call to Action, Special Conference, Association for 

Professionals in Infection Control (APIC), Orlando, FL – The Clinical and 

Financial Impact of Clostridium difficile in Healthcare Facilites

March 2009 Society for Healthcare Epidemiology of America Annual Meeting, San Diego, CA 

– Meet the Consultant: Clostridium difficile Infection

March 2009 Society for Healthcare Epidemiology of America Annual Meeting, San Diego, CA, 

C. difficile and the Role of the Environment Symposium – Implementing Effective 

CDI Prevention Programs

April 2009 Annual Meeting of Clinical Pharmacists, Satellite Symposium, Orlando, FL –

Changing Epidemiology and Economic Burden of Clostridium difficile

April 2009 Springfield Area Regional Association for Professionals in Infection Control 

(APIC) conference, Springfield, MO – Prevention of Clostridium difficile Infection

November 2009 GASTRO 2009, 1st Annual Joint Meeting of the United European 

Gastroenterology Federation (UEGF), World Gastroenterology Organisation 

(WGO), World Organisation of Digestive Endoscopy (OMED) and British Society 

of Gastroenterology (BSG), London, England – Clostridium difficile: The Most 

Rapidly Rising Pathogen?

March 2010 5

th Decennial International Conference on Healthcare-Associated Infection, Joint 

Meeting of the Society for Healthcare Epidemiology of America, Centers for 

Disease Control and Prevention, Association for Professionals in Infection 

Control, and the Infectious Diseases Society of America, Atlanta, GA -

Prevention of Healthcare-Associated C. difficile: What Works?

March 2010 5

th Decennial International Conference on Healthcare-Associated Infection, Joint 

Meeting of the Society for Healthcare Epidemiology of America, Centers for 

Disease Control and Prevention, Association for Professionals in Infection 
Curriculum Vitae

Erik Richard Dubberke, MD, MSPH

7

Control, and the Infectious Diseases Society of America, Atlanta, GA – Infection 

Control for Immunocompromised Patients

July 2010 International Conference on Emerging Infectious Diseases, Atlanta, GA -

Emerging bacterial infections and transplantation, including Clostridium difficile

October 2010 Colorado Infection Prevention Collaborative, Denver, CO – Clostridium difficile

Infection: Preventing the Most Common Healthcare-Associated Infection

October 2010 Infectious Diseases Society of America Annual Meeting, Vancouver, BC - . C. 

difficile: What’s New with Prevention and Treatment

November 2010 Illinois Clostridium difficile Infection Quality Improvement Kick-Off Meeting, 

Collinsville, IL – Diagnosing and Preventing Clostridium difficile Infection

March 2011 Beef Industry Safety Summit, Dallas, TX – You are What You Eat: Clostridium

difficile and You

April 2011 Society for Healthcare Epidemiology of America Annual Meeting, Dallas, TX –

What’s in a Name? Does Which We Call Clostridium difficile Infection by any 

other name Smell as Sweet?

May 2011 American Society of Microbiology Annual Meeting, New Orleans, LA – Update on 

C. difficile Epidemiology and Pathogenesis: Implications for the Healthcare 

Setting

July 2011 Society for Healthcare Epidemiology of America, 15th Annual Fellows Course in 

Hospital Epidemiology, Baltimore, MD – Gastrointestinal Diseases including C. 

difficile and Norovirus

August 2011 Society for Healthcare Epidemiology of America, Healthcare Associated Infection 

Regional Training, Region 5, Chicago, IL – Preventing Clostridium difficile 

Infection

September 2011 Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 

IL – Clostridium difficile in the Community

September 2011 Medicine Grand Rounds, Barnes-Jewish Hospital, Washington University School 

of Medicine, St. Louis, MO – Clostridium difficile in the 21st Century

May 2012 Rochester General Hospital Association Teaching Fellowship, Rochester, NY –

Advances in Clostridium difficile Infection

May 2012 St. Louis chapter of Society for Hospital Medicine, St. Louis, MO – Clostridium 

difficile Infection Update

July 2012 The 9th National Seminar on Infection Control, Rayong, Thailand – Infection 

Control Emergencies In Transplant Recipients

July 2012 The 9th National Seminar on Infection Control, Rayong, Thailand – Clostridium 

difficile Microbiology

July 2012 The 9th National Seminar on Infection Control, Rayong, Thailand – Clostridium 

difficile Epidemiology and Prevention

July 2012 The 9th National Seminar on Infection Control, Rayong, Thailand – Infection 

Control in Transplant Recipients

August 2012 Infectious Diseases Society of St. Louis, St. Louis, MO – Challenges of 

Clostridium difficile Infection

November 2012 12th Annual Infectious Diseases Conference, Washington University School of 

Medicine, St. Louis, MO – Evidence Based Management of Invasive Fungal 

Infections

November 2012 Clostridium difficile Expert Meeting, Tokyo, Japan – Clostridium difficile 

Epidemiology in the United States

November 2012 Clostridium difficile Infectious Diseases Study Group, Kyoto, Japan, - Clostridium 

difficile Infection Surveillance in the United States and Impact of Testing

March 2013 Association for Professionals in Infection Control an Epidemiology (APIC)

Clostridium difficile Educational and Consensus Conference, Baltimore, MD –

Current Research and Limitations Related to Clostridium difficile

April 2013 Health Care Excel QIO, Kentucky Improve Individual Patient Care AIM, 

Louisville, KY – Prevention of Clostridium difficile Infection
Curriculum Vitae

Erik Richard Dubberke, MD, MSPH

8

April 2013 Health Care Excel QIO, Indiana Improve Individual Patient Care AIM, 

Indianapolis, IN – Clostridium difficile Infection Prevention

April 2013 Beijing International Forum on Infection Control, Beijing, China – International 

Practices on Diagnosis, Treatment, and Prevention of Clostridium difficile 

Infection

April 2013 Guangzhou Regional Congress, Guangzhou, China – Diagnosis and 

Management of Clostridium difficile Infection

May 2013 Society for Healthcare Epidemiology of America (SHEA) Spring 2013 Conference 

– Sporicidal Agents for Environmental Disinfection, Con: Not Important in the 

Control of Clostridium difficile

October 2013 ID Week, Annual Joint Meeting of the Infectious Diseases Society of America, 

the Society for Healthcare Epidemiology of America, HIV Medical Association, 

and Pediatric Infectious Diseases Society – Diagnosis of Clostridium difficile 

Infection in Children

October 2013 Bi-State Infectious Diseases Conference, St. Louis, MO – Clostridium difficile 

Infections

February 2014 CDI17 Kick-off Meeting, National Institute of Infectious Diseases, Tokyo, Japan –

Update of Clostridium difficile Epidemiology: A Global Perspective

February 2014 Medicine Grand Rounds, Missouri Baptist Medical Center, St. Louis, MO –

Clostridium difficile Infection Update

March 2014 Washington University Medicine Resident Conference, St. Louis, MO –

Recurrent Clostridium difficile Infection

March 2014 Otolaryngology Grand Rounds, Washington University, St. Louis, MO – Current 

Updates and Management of Clostridium difficile Infection

May 2014 American Society of Clinical Oncology Annual Meeting, Chicago, IL – Clostridium 

difficile Infection: Minimizing the Impact

July 2014 World Transplant Congress Annual Meeting, San Francisco, CA – Clostridium 

difficile Infection in Transplantation

October 2014 ID Week, Annual Joint Meeting of the Infectious Diseases Society of America, 

the Society for Healthcare Epidemiology of America, HIV Medical Association, 

and Pediatric Infectious Diseases Society – Pro: Reducing C. difficile Crosstransmission in Healthcare Facilities is the Most Effective Means of Preventing C. 

difficile Infection

May 2015 5

th International Clostridium difficile Symposium, Bled, Slovenia – Clostridium 

difficile Transmission and Future Prevention Strategies

July 2015 The 12th National Seminar on Infection Control, Pattaya, Thailand – Clostridium 

difficile Infection: What the Infection Preventionist Should Know

July 2015 The 12th National Seminar on Infection Control, Pattaya, Thailand – Infection 

Control In Transplant Patients

July 2015 The 12th National Seminar on Infection Control, Pattaya, Thailand – Surgical Site 

Infection and Catheter Associated Urinary Tract Infection Surveillance: NHSN 

Definitions and Updates

July 2015 The 12th National Seminar on Infection Control, Pattaya, Thailand – Surgical Site 

Infections In Uncommon Procedures

Nov 2015 13th Galaxy of Gastroenterology, St. Louis, MO – C. difficile: Reducing 

Recurrences

Mar 2016 Vanderbilt University School of Medicine, Medicine Grand Rounds, Nashville, TN 

– Clostridium difficile Infection: Past, Present, and Future

Apr 2016 European Congress on Clinical Microbiology and Infectious Diseases, 

Amsterdam, The Netherlands, Integrated Symposium – Epidemiology of C. 

difficile Infection and Recurrent C. difficile Infection

Apr 2016 Visiting Professor, Lieden University, Leiden, the Netherlands; Host: Prof. Dr. Ed 

Kuijper
Curriculum Vitae

Erik Richard Dubberke, MD, MSPH

9

May 2016 The Society for Healthcare Epidemiology of America Spring Conference, Atlanta, 

GA – CON: Alcohol Hand Rub is Fine for Prevention of Clostridium difficile 

Infection

May 2016 Digestive Diseases Week, San Diego, CA - Risk Factors for Clostridium difficile 

Infection and Preventive Practice in 2016

July 2016 C. difficile Reduction Quality and Safety Summit, Mercy Healthcare, Chesterfield, 

MO – The Biology of C. difficile

July 2016 Anaerobe Society of America Congress, Nashville, TN – Safety and Efficacy 

RBX2660 for Recurrent Clostridium difficile Infection

Oct 2016 American College of Gastroenterology Annual Scientific Meeting, Las Vegas, NV 

– Treating a Difficile Problem: Current Status

Oct 2016 IDWeek, New Orleans, LA – The Role of the Stewardship Team in the 

Management of Clostridium difficile Infection

May 2017 Digestive Diseases Week, Chicago, IL – The Gut Microbiome and Clostridium 

difficile

May 2017 XVIII Congress of the Asociacion Panamericana de Infectologia, Panama City, 

Panama – Management and Prevention of Clostridium difficile Infection

May 2017 XVIII Congress of the Asociacion Panamericana de Infectologia, Panama City, 

Panama – Best Intervention Ever

Jul 2017 21st Annual Fellows’ Course in Healthcare Epidemiology, Infection Prevention, 

and Antimicrobial Stewardship, Providence, RI – Prevention of Clostridium 

difficile Infection and Other Causes of Diarrhea

Jul 2017 21st Annual Fellows’ Course in Healthcare Epidemiology, Infection Prevention, 

and Antimicrobial Stewardship, Providence, RI – Infection Prevention Strategies 

for Immunocompromised Hosts and Fungal Disease

Aug 2017 Illinois Health and Hospital Association, C. diff Improvement Action Network, 

Naperville, IL – Prevention of Clostridium difficile Infection

Aug 2017 Midwest Alliance for Patient Safety, Naperville, IL – Optimizing Patient Safety: 

Diagnosis, Treatment, and Prevention of Clostridium difficile Infection

Sept 2017 CDC, Microbiome Indices for Antibiotic Resistance Outcomes Meeting, Atlanta, 

GA – Microbiome Indices, Regulatory Hurdles and Levels of Evidence: From the 

Bench to Improving Patient Outcomes

Oct 2017 IDWeek, San Diego, CA – Clostridium difficile Infection: Focus on Prevention

Oct 2017 15th Galaxy of Gastroenterology, St. Louis, MO – Fecal Microbiota 

Transplantation: A Clinician’s Guide

Sept 2018 NIAID, Vaccines Against C. difficile Infection: A Roadmap to the Future, 

Bethesda, MD – Clostridium difficile Infection: Current Control Measures

Sept 2018 NIAID, Vaccines Against C. difficile Infection: A Roadmap to the Future, 

Bethesda, MD – Clostridium difficile Infection: Targeting Populations for 

Vaccination

Oct 2018 IDWeek Premeeting Workshop, San Francisco, CA - Use of Fecal Microbiota 

Transplantation (FMT) Beyond Recurrent C. difficile

Oct 2018 IDWeek, San Francisco, CA – Fecal Microbiota Transplants in Infectious 

Diseases

Apr 2019 Society for Healthcare Epidemiology of America Annual Spring Meeting, Boston, 

MA – The Future of Clostridioides difficile infection Prevention

May 2019 Rush University Medical Center Department of Internal Medicine Grand Rounds, 

Chicago, IL – Clostridioides difficile Infection Guideline Update: Understanding 

the Data Behind the Recommendations

Oct 2019 University of Montreal College of Pharmacy 100 Year Anniversary Centennial 

Keynote Lecture day on the Microbiome, Montreal, Quebec, Canada - Emerging 

Prevention Strategies for Clostridioides difficile infection: What Does the Future 

Hold?
Curriculum Vitae

Erik Richard Dubberke, MD, MSPH

10

BOARD MEMBERSHIPS

2006-Present National Comprehensive Cancer Center Network (NCCN), Prevention and 

Treatment of Cancer-Related Infections Guideline Committee

RESEARCH SUPPORT

A. Governmental

a. Past support

Prevention Epicenters Program: UR8/CCU715087-03 (PI: Fraser) – CDC: 1/20/01 – 1/20/06; 

investigator

Clostridium difficile-associated disease: UR8/CCU715087-06/1 (PI: Fraser) – CDC: 9/01/04-

1/31/07; investigator

Washington University Institute of Clinical and Translational Sciences; Research Education, 

Training and Career Development (formerly K12 Multidisciplinary Clinical Research Career 

Development Program): 1 UL1 RR024992-01 (PI: Polonsky); 1 KL2 RR024994-01 (PI: Fraser) 

(formerly 1K12RR02324901 (PI: Fraser)) – NCRR: 9/01/07 – 5/31/12; scholar (2 year 

commitment)

Mortality in Transplant patients with Aspergillosis: K23AI064613 (PI: Baddley) 9/1/07 to 8/31/10; 

subcontract

Dynamics of Clostridium difficile transmission and infection control measures in health-care 

settings: Food and Waterborne Diseases Integrated Research Network, N01-AI-30054 (PI: 

Grohn) – NIAID: 6/30/09 to 9/30/10; subcontract, site PI

Prevention Epicenters Program: 1UO1CI000333-01 (PI: Fraser) – CDC: 1/20/06-1/20/11; 

investigator

Invasive fungal infections in ultra-high-risk transplant recipients: 5U01CI000283-03 (PI: Silveria, 

UPMC) – CDC: 9/1/04-8/31/09; sub contract, site PI

C. difficile Disease in Stem Cell Transplant Recipients: 1K23AI065806-01A2 (PI: Dubberke) –

NIAID: 2/1/09 – 1/31/12; Primary investigator

Validation and Modeling of a C. difficile Infection Risk Prediction Index: 1R21NR011362-01 –

NINR: 7/01/09 – 6/30/11; Primary Investigator

Clostridium difficile Infection: Redefining the Role of the Asymptomatic Host: P30 DK52574 (PI: 

Davidson) – NIDDK: 5/1/10 to 4/30/11 and 5/1/11 to 4/30/12; pilot and feasibility award

Surgical Site and Clostridium difficile Infections after Ambulatory Surgery: R01 HS019713 

(Olsen; PI) – AHRQ: 10/1/10 – 9/30/13; investigator

Organ Transplant Infection Detection and Prevention Program: 1U01CK000134-01 (PI: Silveria, 

UPMC) – CDC: 9/1/10-8/29/15; sub contract, site PI

Use of Needleless Connectors to Prevent Bloodstream Infections in Hemodialysis: CDC Task 

Order 200-2011-42070-002 (PI: Dubberke) – CDC: 8/1/2013 – 4/1/2015

Prevention Epicenters Program: 1U54CK000162-01 (PI: Fraser) – CDC: 3/1/2011-02/29/2016; 

investigator
Curriculum Vitae

Erik Richard Dubberke, MD, MSPH

11

Studies to Prevent Infections and Protect Healthcare Workers in Hospitals: 3U54CK000162-

05S1 (PI: Fraser) – CDC: 4/1/2015-2/29/16

Fecal Microbiome Restoration after Antimicrobials with Autologous Fecal Microbiota Therapy:

3U54CK00162-03S1 (PI: Dubberke) – CDC: 8/15/2013 – 8/14/2014

Impact of Fecal Transplantation on Resistant Organism Carriage and the Resistome: 

3U54CK000162-04S1 (PI: Dubberke) – CDC: 9/1/14 – 8/31/15

Intestinal Metabolomic Factors Affecting Clostridium difficile Colonization and Infection:

CDC Broad Agency Announcement 200-2016-91965 (PI: Henderson) – CDC: 9/30/2016 –

9/29/2017; investigator

Prospective Study Characterizing Fecal Microbiome Disruptions During and After Receipt of 

Antimicrobials: CDC Broad Agency Announcement 200-2016-91962 (PI: Kwon) – CDC: 

9/30/2016 – 9/29/2017; investigator

Modeling and Control of Environmentally Transmitted Pathogens:

R01GM113239 (PI: Lanzas) – NIGMS: 8/1/14 – 4/30/19; sub contract, investigator

b. Current Support

Clostridium difficile Nucleic Acid Amplification Test Cycle Threshold Value Associated 

Environmental Contamination (CONTAM Study): 200-2018-02926, CDC 10/1/18 – 9/30/19; PI

Double blinded, randomized controlled Trial of Oral vancomycin versus placebo in hospitalized 

patients with diarrhea and stool toxin negative but nucleic acid amplification test positive for 

toxigenic Clostridium difficile (TOX NEG trial): 200-2017-96178; CDC 09/30/17 – 09/29/18; PI

Understanding and Preventing Clostridium difficile Transmission from Asymptomatically 

Colonized Patients: R01 HS025456-01 (PI: Morgan) – AHRQ: 8/1/17 to 5/31/2021; site PI

Washington University & BJC Epi-Center for Prevention of Healthcare Associated Infections: 

1U54CK000482 (PI: Fraser); CDC: 07/01/16 – 6/30/2020; investigator

Predictors of Recurrent Multidrug Resistant UTI and Impact of FMT on Recurrence: (PI: 

Dubberke); CDC 07/01/16 – 6/30/2020; project PI

Multicenter Collaborative Project: MAriMbA: The Microbiome and Mdro Acquisition Project: 

U54CK000481 (PI: Hayden); CDC 07/01/16 – 6/30/2020; site PI

B. Non-governmental

a. Past support

A Randomized, Double-Blind Study of GT267-004 Versus Vancomycin, and GT267-004 Versus 

Metronidazole, in Patients With C.Difficile - Associated Diarrhea: Genzyme; Clinical trial; site 

primary investigator: 9/15/05 – 11/15/06

Protocol No: 1263-301, A Randomized, Double-Blind Study to Assess the 

Efficacy and Safety of Prophylactic use of Maribavir Versus Oral Ganciclovir for 

the Prevention of Cytomegalovirus Disease in Recipients of Orthotopic Liver 

Transplants: Viropharma; Clinical trial; site primary investigator: 9/15/07 – 9/14/09

Development and Validation of a Clostridium difficile-Associated Disease Risk Index: (PI: 

Dubberke) – Barnes-Jewish Hospital Foundation, Investigator initiated 4/01/07 – 3/31/09; PI
Curriculum Vitae

Erik Richard Dubberke, MD, MSPH

12

Prospective Observational Study of Nosocomial Clostridium difficile Toxin Antibody 

Concentrations, Incidence, and Recurrence. Merck; Clinical trial, site Primary Investigator, Codesigned study: 1/15/09 – 1/14/12

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the 

Safety and Efficacy of VP 20621 For Prevention of Recurrence of Clostridium difficile Infection 

(CDI) in Adults Previously Treated for CDI. Viropharma. Clinical trial, Site PI: 8/1/11 – 11/30/12

A Phase 2, Open-label Clinical Trial Demonstrating the Safety of RBX2660 Microbiota 

Suspension for the Treatment of Recurrent Clostridium difficile-associated Diarrhea. Rebiotix, 

Clinical trial, Site PI: 9/1/13 to 7/31/14

Effectiveness of Provodine and Provodine T to Prevent and Remove Clostridium difficile Spore 

Hand Contamination. Microdermis. Investigator initiated, PI 12/12/13 – 7/31/15

Risk factors and Outcomes of Recurrent Clostridium difficile infection. Optimer. Invetigator 

initiates, PI. 10/20/10 – 12/15/14

Epidemiology, Risk Factors, and Outcomes of Clostridium difficile Infection in Medicare and 

Hospitalized Patients. Sanofi Pasture. Investigator initiated, PI. 12/21/12 – 5/20/15

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the 

Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody 

to Clostridium difficile toxin A), MK-6072 (Human Monoclonal Antibody to Clostridium difficile

toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium difficile toxin A and toxin 

B) in Patients Receiving Antibiotic Therapy for Clostridium difficile Infection. Merck. Site PI. 

11/1/12 – 2/28/15

DEFLECT-1: A Phase 3b Multi-Center, Double-Blind, Randomized, Placebo Controlled Study to

Demonstrate the Safety and Efficacy of Fidaxomicin for Prophylaxis against Clostridium difficileAssociated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation. Optimer. 

Site PI. 2/1/13 to 6/15/15

A Phase 2B Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study 

Demonstrating the Efficacy and Safety of Rebiotix RBX2660 (microbiota suspension) for the 

Treatment of Recurrent Clostridium difficile Infection. Rebiotix. Study site PI. 11/1/14 to present

Effect of Limiting Sequential Clostridium difficile Testing on Patient Care Outcomes. The 

Foundation for Barnes-Jewish Hospital. PI. 7/1/14 to 6/30/16

Analysis of the Health Care Utilization and Trajectory Before and After Clostridium difficile 

Infection. Sanofi-Pasteur. PI. 8/20/14 – 11/28/17 

Epidemiology of Clostridium difficile Infection in Japan. Sanofi-Pasteur. PI 10/6/15 to present

b. Current support

Administrative database analyses to determine the incidence and outcomes of Clostridium 

difficile infection and impact of a CDI vaccine. Pfizer. PI. 11/2017-present

Phase 1b/2a Evaluation of the Safety and Tolerability of SYN-004 in Adult Allogeneic 

Hematopoietic Cell Transplantation Recipients. Synthetic Biologics. PI. 08/2019-present
Curriculum Vitae

Erik Richard Dubberke, MD, MSPH

13

CLINICAL TITLES AND RESPONSIBILITIES

2003-2007 Faculty Lecturer, St. Louis STD/HIV Prevention Training Center, Washington 

University School of Medicine

2004-2013 Medical Attending, John Cochran Veterans Administration Hospital, St. Louis, 

MO (current status: WOC)

2005-Present Associate Hospital Epidemiologist, Transplant and Oncology Units, C. difficile, 

Barnes-Jewish Hospital, St. Louis, MO

2005-Present Medical Director, Infection Control, Missouri Baptist Medical Center, St. Louis, 

MO

2005-Present Attending Physician, Barnes-Jewish Hospital

2007 Interim Medical Director, Sexually Transmitted Disease Clinic, St. Louis County

2005-Present Clinical Director, Transplant Infectious Diseases: Developed inpatient consult 

service, outpatient clinic, and teaching curriculum; Member of BJH Transplant 

Steering Committee

TEACHING TITLES AND RESPONSIBILITIES

WUSM III/IV, Resident, and Fellow training

2005-Present Outpatient Transplant Infectious Diseases Clinic Attending

2005-Present Inpatient Transplant Infectious Diseases Service Attending

2006-Present Lecturer, Infectious Diseases Core Curriculum Series: Topics covered – VRE, C. 

difficile, infections in stem cell transplant recipients, infections in solid organ 

transplant recipients

WUSM I and II Courses

2000-2003 Small group leader. Practice of Medicine. Clinical Skills

2002-Present Small group leader, Infectious Diseases Course

2003-Present Small group leader, Practice of Medicine. Infection Control

2004-2007 Small group leader. Practice of Medicine. History and Physical

2006-2017 Lecturer, Infectious Diseases Course, WUSM II - Non-HIV Immunocompromised 

Hosts

2007-2010 Small group leader. Practice of Medicine. Scientific Methods

TRAINING / MENTEE RECORD

Current Trainees / Mentees

2014-Present Jennie H. Kwon, DO, MSCI, assistant professor, infectious diseases division, 

Washington University School of Medicine

2015-Present Merilda Blanco Guzman, MD, instructor in medicine, infectious diseases division, 

Washington University School of Medicine

2015-Present Larry K. Kociolek, MD, MSCI, instructor in pediatrics, infectious diseases division, 

Northwestern University

2017-Present William McCoy, MD, PhD, instructor in medicine, dermatology division, 

Washington University School of Medicine

2018-Present Adriana Rauseo, MD, fellow, infectious diseases division, Washington University

School of Medicine

Past Trainees / Mentees

2006-2007 Leticia Luz, MD, internal medicine resident, Barnes-Jewish Hospital

2009-2011 Amelia Kasper, MD, MHS, internal medicine resident, Barnes-Jewish Hospital

2009-2011 Linda Bobo, MD, PhD, infectious diseases fellow, Washington University School 

of Medicine

2010-2012 Zhuolin (Julia) Han, MD, infectious diseases fellow, Washington University

School of Medicine
Curriculum Vitae

Erik Richard Dubberke, MD, MSPH

14

2011-2013 Jonathan Baghdadi, MD, internal medicine resident, Barnes-Jewish Hospital

2011-2014 Faisal Al Asmari, MBBS, epidemiology fellow, Washington University School of 

Medicine

2014-2015 Allison L. Nazinitsky, MD, infectious diseases fellow, Washington University

School of Medicine

BIBLIOGRAPHY

Publications

1. Kumar GN, Dubberke E, Rodrigues AD, Roberts E, Dennisen JF. Identification of Cytochrome 

p450(s) Involved in the Human Liver Microsomal Metabolism of the Thromboxane A2 Inhibitor 

Seratrodast (ABT-73001). Drug Metab Dispos 1997 Jan; 25(1):110-5. PMCID: Not applicable

2. Dubberke E, Razavi B, Johnson R. Serretia marscecens necrotizing fasciitis in a Bone Marrow 

Transplant Patient. Infec Dis Clin Pract 2002; 11(1): 25-27 PMCID: Not applicable

3. Dubberke ER, Fraser V. Antibiotic Cycling and Other Strategies of Antibiotic Use in Slowing and 

Reversing Antibiotic Resistance. Infections in Medicine 2004; 21 (11): 544-56 PMCID: Not 

applicable

4. Khoury J, Dubberke ER, Devine SM. Fatal Case of Prothecosis in a Hematopoietic Stem Cell 

Transplant Recipient after Infliximab Treatment for Graft Versus Host Disease. Blood 2004; 103 (10): 

3414-5 PMCID: Not applicable

5. Dubberke ER, Fraser V. Strategies for Preventing and Reversing Antimicrobial Resistance: The Role 

of Antibiotic Cycling. Drug Benefit Trends 2005; 17 (2): 63-75 PMCID: Not applicable

6. Dubberke ER, Tu B, Rivet D, Storch G, Apisarnthanarak A, Schmidt R, Weiss S, Polish L. Acute 

Meningoencephalitis Caused by Adenovirus Serotype 26. J Neurovirol 2006; 12: 235-240. PMCID: 

Not applicable

7. Dubberke ER, Reske K, McDonald LC, Fraser VJ. ICD-9 Codes and Surveillance for Clostridium 

difficile-Associated Disease. Emerg Infect Dis. 2006; 12: 1576-1579 PMCID: PMC3290935

8. Dubberke ER, Hollands J, Georgantopolous P, Augustin K, DiPersio J, Mundy L, Khoury H. 

Vancomycin-Resistant Enterococcal Bloodstream Infections on a Hematopoietic Stem Cell Transplant 

Unit: Are the Sick Getting Sicker? Bone Marrow Transplant. 2006; 38: 813-819 PMCID: Not 

applicable

9. McMullen KM, Zack J, Coopersmith CM, Kollef M, Dubberke ER, Warren DK. The Use of 

Hypochlorite Solution to Lower Rates of Clostridium difficile-Associated Diarrhea. Infect Control Hosp 

Epidemiol. 2007; 28: 205-207 PMCID: Not applicable

10. Dubberke ER, Sadhu J, Gatti R, Reske K, DiPersio J, Devine S, Fraser V. Severity of Clostridium 

difficile-Associated Disease in Allogeneic Stem Cell Transplant Recipients: Evaluation of a CDAD 

Grading Scale. Infect Control Hosp Epidemiol. 2007; 28: 208-211 PMCID: Not applicable

11. McDonald LC, Coignard B, Dubberke ER, Song X. Recommendations for Surveillance of Clostridium 

difficile-Associated Disease. Infect Control Hosp Epidemiol. 2007; 28: 140-145 PMCID: Not 

applicable

12. Dubberke ER, Reske KA, Noble-Wang J, Thompson A, Killgore G, Mayfield J, Camins B, Woeltje K, 

McDonald J, McDonald LC, Fraser VJ. Prevalence of Clostridim difficile Environmental Contamination 

and Strain Variability in Multiple Healthcare Facilities. Am J Infect Control. 2007; 35: 315-8. PMCID: 

Not applicable

13. Rodemann JF, Dubberke ER, Reske KA, Seo DH, Stone CD. Increasing Incidence of Clostridium 

difficile Infection in Inflammatory Bowel Disease. Clin Gastro and Hep. 2007; 5: 339-344. PMCID: Not 

applicable

14. Dubberke ER, Reske KA, Olsen MA, McDonald LC, McMullen KM, Mayfield JL, Fraser VJ. 

Evaluation of “CDAD pressure” as a risk factor for Clostridium difficile-Associated Disease. Arch 

Intern Med. 2007; 167: 1092-1097. PMCID: Not applicable

15. Lawrence SJ, Dubberke ER, Johnson S, Gerding D. Clostridium difficile-Associated Disease 

Treatment Response Depends on Definition of Cure. Clin Infect Dis. 2007; 45: 1648 PMCID: Not 

applicable
Curriculum Vitae

Erik Richard Dubberke, MD, MSPH

15

16. Dubberke ER, Reske KA, Yan Y, McDonald LC, Fraser VJ. Clostridium difficile-Associated Disease 

in a Setting of Endemicity: Identification of Novel Risk Factors. Clin Infect Dis. 2007; 45: 1543-9. 

PMCID: Not applicable

17. Dubberke ER, Reske KA, Olsen MA, McDonald LC, Fraser VJ. Short and Long-Term Attributable 

Costs of Clostridium difficile-Associated Disease in Nonsurgical Inpatients. Clin Infect Dis. 2008; 

46:497-504. PMCID: Not applicable

18. Segal BH, Freifeld AG, Baden LR, Brown AE, Casper C, Dubberke ER, Gelfand M, Greene JN, Ison 

MG, Ito JI, Karp JE, Kaul DR, King E, Mackler E, Marcucci G, Montoya JG, Engemann AM, Rolston 

K. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw. 2008 

Feb;6(2):122-74. PMCID: Not applicable

19. Fritz JM, Brielmaier BD, Dubberke ER. Micafungin for the prophylaxis and treatment of Candida 

infections. Expert Rev Anti Infect Ther. 2008 Apr;6(2):153-62. PMCID: Not applicable

20. Dubberke ER, Weil GJ. A woman from Honduras with a painful forearm and fever. Am J Trop Med 

Hyg. 2008 May;78(5):697-8. PMCID: Not applicable

21. Dubberke ER, Butler AM, Reske KA, Agniel D, Olsen MA, D’Angelo G, McDonald LC, Fraser VJ. 

Attributable Outcomes of Endemic Clostridium difficile-Associated Disease in Nonsurgical Patients.

Emerg Infect Dis. 2008; 14 (7):1031-8. PMCID: PMC2600322

22. Dubberke ER, Sadhu J, Gatti R, Reske K, DiPersio J, Devine S, Fraser V. Reply to Jaber et al. Infect 

Control Hosp Epidemiol. 2008; 29: 189-90. PMCID: Not applicable

23. Riddle DJ, Dubberke ER. Clostridium difficile Infection in Solid Organ Transplant Recipients. Curr 

Opin Organ Transplant. 2008; 13: 592-600. PMCID: Not applicable

24. Dubberke ER, Reske KA, yan Y, Olsen MA, Fraser VJ. Reply to Goorhuis et al. Clostridium difficileAssociated Disease (CDAD) Pressure: A Better Measure of CDAD Exposure than Length of Stay or 

Ward. Clin Infect Dis. 2008; 47:430-1. PMCID: Not applicable

25. Dubberke ER, Gerding DN, Classen D, Arias KM, Podgorny K, Anderson DJ, Burstin H, Calfee DP, 

Coffin SE, Fraser V, Griffin FA, Gross P, Kaye KS, Klompas M, Lo E, Marschall J, Mermel LA, Nicolle 

L, Pegues DA, Perl TM, Saint S, Salgado C, Weinstein RA, Wise R, Yokoe DS. Implementation 

Strategies for Prevention and Monitoring of Clostridium difficile-Associated Disease in Acute Care 

Hospitals. Infect Control Hosp Epidemiol. 2008; Suppl 1: S81-92. PMCID: Not applicable

26. Marschall J, Mermel LA, Classen D, Arias KA, Podgorny K, Anderson DJ, Burstin H, Calfee DP, 

Coffin SE, Dubberke ER, Fraser V, Gerding DN, Griffin FA, Gross P, Kaye KS, Klompas M, Lo E, 

Nicolle L, Pegues DA, Perl TM, Saint S, Salgado C, Weinstein RA, Wise R, Yokoe DS. 

Implementation Strategies for the Prevention and Monitoring of Central Line-Associated Bloodstream 

Infections in Acute Care Hospitals. Infect Control Hosp Epidemiol. 2008; Suppl 1: S22-30. PMCID: 

Not applicable

27. Lo, E, Nicolle L, Classen D, Arias KM, Podgorny K, Anderson DJ, Burstin H, Calfee DP, Coffin SE, 

Dubberke ER, Fraser V, Gerding DN, Griffin FA, Gross P, Kaye KS, Klompas M, Marschall J, Mermel 

LA, Pegues DA, Perl TM, Saint S, Salgado C, Weinstein RA, Wise R, Yokoe DS. Implementation 

Strategies for the Prevention and Monitoring of Catheter-Associated Urinary Tract Infections in Acute 

Care Hospitals. Infect Control Hosp Epidemiol. 2008; Suppl 1: S41-50 PMCID: Not applicable

28. Calfee DP, Salgado C, Classen D, Arias KM, Podgorny K, Anderson DJ, Burstin H, Coffin SE, 

Dubberke ER, Fraser V, Gerding DN, Griffin FA, Gross P, Kaye KS, Klompas M, Lo E, Marschall J, 

Mermel LA, Nicolle L, Pegues A, Perl TM, Saint S, Weinstein RA, Wise R, Yokoe DS. Implementation 

Strategies for Prevention and Monitoring of Methicillin-Resistant Staphylococcus aureus in Acute 

Care Hospitals. Infect Control Hosp Epidemiol.2008; Suppl 1: S62-80. PMCID: Not applicable

29. Anderson DJ, Kaye KS, Classen D, Arias KM, Podgorny K, Burstin H, Calfee DP, Coffin SE, 

Dubberke ER, Fraser V, Gerding DN, Griffin FA, Gross P, Klompas M, Lo E, Marschall J, Mermel LA, 

Nicolle L, Pegues DA, Perl TM, Saint S, Salgado C, Weinstein RA, Wise R, Yokoe S. Implementation 

Strategies for the Prevention and Monitoring of Surgical Site Infections in Acute Care Hospitals. Infect 

Control Hosp Epidemiol. 2008; Suppl 1: S51-61. PMCID: Not applicable

30. Coffin SE, Klompas M, Classen D, Arias KM, Podgorny K, Anderson DJ, Burstin H, Calfee DP, 

Dubberke ER, Fraser V, Gerding DN, Griffin FA, Gross P, Kaye KS, Lo E, Marschall J, Mermel LA, 

Nicolle L, Pegues DA, Perl TM, Saint S, Salgado C, Weinstein RA, Wise R, Yokoe DS. 
Curriculum Vitae

Erik Richard Dubberke, MD, MSPH

16

Implementation Strategies for the Prevention and Monitoring of Ventilator-Associated Pneumonia in 

Acute-Care Hospitals. Infect Control Hosp Epidemiol. 2008; Suppl 1: S31-40. PMCID: Not applicable

31. Yokoe DS, Mermel LA, Anderson DJ, Arias KM, Burstin H, Calfee DP, Coffin SE, Dubberke ER, 

Fraser V, Gerding DN, Griffin FA, Gross P, Kaye KS, Klompas M, Lo E, Marschall J, Nicolle L, 

Pegues DA, Perl TM, Podgorny K, Saint S, Salgado C, Weinstein RA, Wise R, Classen D. A 

Compendium of Implementation Strategies for the Prevention and Monitoring of HealthcareAssociated Infections in Acute Care Hospitals. Infect Control Hosp Epidemiol. 2008; Suppl 1: S12-

31—21. PMCID: Not applicable

32. Babcock HM, Merz LR, Dubberke ER, Fraser VJ. Case-control study of clinical features of influenza 

in hospitalized patients. Infect Control Hosp Epidemiol. 2008; 10:921-6. PMCID: Not applicable

33. Dubberke ER, Wertheimer AI. The Economic Burden of Clostridium difficile Infection: A Review of 

the Current Literature. Infect Control Hosp Epidemiol. 2009; Jan;30(1):57-66. PMCID: Not applicable

34. Dubberke ER, McMullen KM, Mayfield JL, Reske KA, Georgantopoulos P, Warren DK, Fraser VJ. 

Hospital-Associated Clostridium difficile Infection: Is It Necessary to Track Community-Onset 

Disease? Infect Control Hosp Epidemiol. 2009; 30:332-7. PMCID: PMC3598605

35. Dubberke ER, Butler AM, Hota B, Khan YM, Mangino JE, Mayer J, Popovich KJ, Stevenson KB, 

Yokoe DS, McDonald LC, Jernigan J, Fraser VJ, CDC Prevention Epicenters Program. Multicenter 

Study of the Impact of Community-Onset Clostridium difficile Infection on Surveillance for C. difficile

Infection. Infect Control Hosp Epidemiol. 2009; 30:518-525. NIHMSID: 464743

36. Schaefer AM, McMullen KM, Mayfield JL, Richmond A, Warren DK, Dubberke ER. Risk factors 

associated with methicillin-resistant Staphylococcus aureus colonization on hospital admission 

among oncology patients. Am J Infect Control. 2009; April 9. e pub ahead of print. PMCID: 

PMC3668339

37. Kun H, Moore A, Mascola L, Steurer F, Lawrence G, Kubak B, Radhakrishna S, Leiby D, Herron R, 

Mone T, Hunter R, Kuehnert M; Chagas Disease in Transplant Recipients Investigation Team. 

Transmission of Trypanosoma cruzi by heart transplantation. Clin Infect Dis. 2009 Jun 1;48:1534-40. 

PMCID: Not applicable

38. Riddle DJ, Dubberke ER.Trends in Clostridium difficile Disease: Epidemiology and Intervention. 

Infections in Medicine. 2009; 26:211-20. NIHMSID: 464766

39. Honda H, Dubberke ER. Clostridium difficile Infection: A Re-Emerging Threat. Mo Med. 2009; 

106:287-91. PMCID: PMC3648223

40. Riddle DI, Dubberke ER. Clostridium difficile Infection in the Intensive Care Unit. Infect Dis Clin North 

Amer. 2009; 23:727-744. PMCID:PMC3598605

41. Arnold HM, McKinnon PS, Augustin KM, Hladnik LM, Casabar E, Reichley RM, Dubberke ER, 

Westervelt P, Ritchie DJ. Assessment of imipenem-cilastatin 500mg q6h, meropenem 1g q8h and 

meropenem 500mg q6h in adult patients with neutropenic fever. Pharmacotherapy. 2009; 29:914-23. 

NIHMSID: 471638

42. Singh N, Aguado JM, Bonatti H, Forrest G, Gupta KL, Safdar N, John GT, Pursell KJ, Muñoz P, Patel 

R, Fortun J, Martin-Davila P, Philippe B, Philit F, Tabah A, Terzi N, Chatelet V, Kusne S, Clark N, 

Blumberg E, Julia EB, Humar A, Houston S, Lass-Flörl C, Johnson L, Dubberke ER, Barron MA, 

Lortholary O. Zygomycosis in Solid Organ Transplant Recipients: a Prospective, Matched CaseControl Study to Assess Risks for Disease and Outcome. J Infect Dis. 2009; 200:1002-11. PMCID: 

Not applicable

43. Sun YH, Aquado JM, Bonatti H, Forrest G, Gupta KL, Safdar N, John GT, Pursell KJ, Munoz P, Patel 

R, Fortun J, Matin-Davila P, Philippe B, Philit F, Tabah A, Terzi N, Chatelet V, Kusne S, Clark N, 

Blumberg E, Julia MB, Humar A, Houston S, Lass-Florl C, Johnson L, Dubberke ER, Barron MA, 

Lortholary O, Singh N, and the Zygomycosis in Transplant Study Group. Pulmonary Zygomycosis in 

Solid Organ Transplant recipients in the Current Era. Am J Transplant. 2009; 9: 2166-71. PMCID: 

Not applicable

44. Dubberke ER, Reske KA, Srivastava A, Sadhu J, Gatti R, Young RM, Rakes LC, Dieckgraefe B, 

DiPersio J, Fraser VJ. Clostridium difficile Infection in Allogeneic Hematopoietic Stem Cell Transplant 

Recipeints: Protective Factors, Risk Factors, and Outcomes. Clin Transpl. 2009; Epub ahead of print.

PMCID: PMC3390201
Curriculum Vitae

Erik Richard Dubberke, MD, MSPH

17

45. Dubberke ER, The A, B, BI, and Cs of Clostridium difficile. Clin Infect Dis. 2009; 49:1148-52. PMCID: 

PMC3649764

46. Litvin M, Reske KA, Mayfield J, McMullin KM, Georgantopoulos P, Copper S, Hoppe-Bauer JE, 

Fraser VJ, Warren DK, Dubberke ER. Identification of a Clostridium difficile - Infection (CDI) Pseudooutbreak and Impact of Repeated Testing, Sensitivity, and Specificity on Perceived Prevalence of 

CDI. Infect Control Hosp Epidemiol. 2009; 30:1166-71. PMCID: PMC3598603

47. Yokoe D, Casper C, Dubberke E, Lee G, Muñoz P, Palmore T, Sepkowitz K, Young JA, Donnelly JP. 

Safe living after hematopoietic cell transplantation. Bone Marrow Transplant. 2009 Oct;44(8):509-19.

PMCID: PMC3103296

48. Yokoe D, Casper C, Dubberke E, Lee G, Muñoz P, Palmore T, Sepkowitz K, Young JA, Donnelly JP. 

Infection prevention and control in health-care facilities in which hematopoietic cell transplant 

recipients are treated. Bone Marrow Transplant. 2009 Oct;44(8):495-507. PMCID: PMC3103296

49. Dubberke ER, Riddle DJ, AST Infectious Diseases Community of Practice. Diagnosis, Treatment, 

and Prevention of Clostridium difficile Infection in Solid Organ Transplant Recipients. Am J 

Transplant. 2009; 9 (Suppl 4): S35-S40. NIHMSID: 464771

50. Dubberke ER, Butler AM, Yokoe DS, Mayer J, Hota B, Mangino JE, Khan YM, Popovich KJ, 

Stevenson KB, McDonald LC, Olsen MA, Fraser VJ, CDC Prevention Epicenters Program. A 

Multicenter Surveillance Study of ICD-9-CM Code Based Hospital-Onset Clostridium difficile Infection 

Surveillance. Infect Control Hosp Epidemiol. 2009. Infect Control Hosp Epidemiol. 2010 

Mar;31(3):262-8. PMCID: PMC3640806

51. Alexander BT, Hladnik LM, Augustin KM, Casabar E, McKinnon PS, Reichley R, Ritchie DJ, 

Westervelt P, Dubberke ER. Use of Cytomegalovirus Intravenous Immune Globulin for the Treatment 

of Cytomegalovirus in Hematopoietic Stem Cell Transplant Patients. Pharmacotherapy. 2010;

30(6):554-561. PMCID: PMC3668347

52. Bobo LD, Dubberke ER. Recognition and Prevention of Hospital-Associated Enteric Infections in the 

Intensive Care Unit. Critical Care Medicine. 2010; 38 (8 Suppl): S324-34. PMCID: PMC3657464

53. Dubberke ER, Butler AM, Yokoe DS, Mayer J, Hota B, Mangino JE, Khan YM, Popovich KJ, Fraser 

VJ, CDC Prevention Epicenters Program. A Multicenter Study of Clostridium difficile Infection Rates 

from 2000-2006. Infect Control Hosp Epidemiol. 2010. 2010 Oct;31(10):1030-7. PMCID: 

PMC3648217

54. Dubberke ER, Prevention of Healthcare-Associated Clostridium difficile: What Works? Infect Control 

Hosp Epidemiol. 2010 Nov;31 Suppl 1:S38-41. PMCID: PMC3648222

55. Dubberke ER, Haslam DB, Lanzas C, Bobo LD, Burnham CD, Grohn YT, Tarr PI. The Ecology and 

Pathobiology of Clostridium difficile Infections: An Interdisciplinary Challenge. Zoonoses Public 

Health. 2011. 25: 4-20. PMCID: PMC3668351

56. Dubberke ER, Yan Y, Reske KA, Butler AM, Doherty J, Pham V, Fraser VJ. Development and 

Validation of a Clostridium difficile Infection Risk Prediction Model. Infect Control Hosp Epidemiol. 

2011. 32: 360-6. PMCID: PMC3649761

57. Lanzas C, Dubberke ER, Lu Z, Reske KA, Grohn YT. Epidemiological Model for Clostridium difficile

Transmission in Healthcare Settings. Infect Control Hosp Epidemiol. 2011. 32: 553-61. PMCID: 

PMC3645005

58. Dubberke ER, Butler AM, Nyazee HA, Reske KA, Yokoe DS, Mayer J, Hota B, Mangino JE, Khan 

YM, Fraser VJ, CDC Prevention Epicenters Program. The Impact of ICD-9-CM Rank-Order on the 

Estimated Prevalence of Clostridium difficile Infections. Clin Infect Dis. 2011. 53(1):20-5. PMCID: 

PMC3110281

59. Bobo LD, Dubberke ER, Kollef M. Clostridium difficile in the Intensive Care Unit: The Struggle 

Continues. Chest. 2011. Chest. 2011 Dec;140(6):1643-53. PMCID: PMC3231962

60. Han Z, McMullen KM, Russo AJ, Copper SM, Warren DK, Dubberke ER. A Clostridium difficile

Infection “Intervention:” Change in Toxin Assay Results in Lower Number of Clostridium difficile

Infection Cases without Changes in Patient Outcomes. Am J Infect Control. 2011. Jul 26. Epub ahead 

of print. NIHMSID: 464780

61. Dubberke ER, Han Z, Bobo L, Hink T, Lawrence B, Hoppe-Bauer J, Burnham CD, Dunne WM. 

Impact of Clinical Symptoms on the Sensitivity and Specificity of Clostridium difficile Diagnostic 

Assays. J Clin Micro. 2011. 49: 2887-93. PMCID: PMC3147743
Curriculum Vitae

Erik Richard Dubberke, MD, MSPH

18

62. McMullen KM, Mayfield JL, Abdul-Hakim, Warren DK, Dubberke ER. Assessing Colectomies due to 

Clostridium difficile Infection: Increases in the Community, Not Referral Center. Am J Infect Control. 

2012. 40 (8): 778-780. PMCID: Not applicable

63. Murphy CR, Avery TR, Dubberke ER, Huang SS. Frequent Hospital Readmissions for Clostridium 

difficile Infection and the Impact on Estimates of Hospital-Associated C. difficile Burden. Infect Control 

Hosp Epidemiol. 2011. Infect Control Hosp Epidemiol. 2012 Jan;33(1):20-8. Epub 2011 Nov 11.

PMCID: PMC3657466

64. Yan Y, Reske KA, Fraser VJ, Colditz GA, Dubberke ER. Using Appropriate Functional Forms for 

Continuous Variables and Improving Predictive Accuracy in Developing the Risk Model of Clostridium 

Difficile Infection. Journal of Data Science 10 (1), 37-49

65. Dubberke ER, Nyazee HA, Yokoe DS, Mayer J, Mangino J, Khan YM, Fraser VJ. Implementing 

Automated Surveillance for Tracking Clostridium difficile Infection at Multiple Healthcare Facilities.

Infect Control Hosp Epidemiol. 2012 Mar;33(3):305-8. PMCID: PMC3649760

66. Kasper AM, Nyazee HA, Yokoe DS, Mayer J, Mangino J, Hota B, Khan YM, Fraser VJ, Dubberke 

ER. A Multicenter Study of Clostridium difficile Infection-Related Colectomy, 2000-2006. Infect 

Control Hosp Epidemiol. 2012 May;33(5):470-6. PMCID: PMC3657463

67. Dubberke ER, Olsen MA. Burden of Clostridium difficile on the Healthcare System. Clin Infect Dis. 

2012. 55(S2):S88-92. PMCID: PMC3388018

68. Dubberke ER. Clostridium difficile infection: The scope of the problem. J Hosp Med. 2012 Mar;7 

Suppl 3:S1-4. PMCID: Not applicable

69. Dubberke ER. Strategies for the prevention of Clostridium difficile Infection. J Hosp Med. 2012 Mar;7 

Suppl 3:S4-7. PMCID: Not applicable

70. Winston DJ, Saliba F, Blumberg E, Abouljoud M, Garcia-Diaz JB, Goss JA, Clough L, Avery R,

Limaye AP, Ericzon BG, Navasa M, Troisi RI, Chen H, Villano SA, Uknis ME; 1263-301 Clinical 

Study Group. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of 

cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter 

controlled trial. Am J Transplant. 2012 Nov;12(11):3021-30. Epub 2012 Sep 4. PMCID: Not 

applicable

71. Kamboj M, Son C, Cantu S, Chemaly RF, Dickman J, Dubberke E, Engles L, Lafferty T, Liddell G, 

Lesperance ME, Mangino JE, Martin S, Mayfield J, Mehta SA, O'Rourke S, Perego CS, Taplitz R, 

Eagan J, Sepkowitz KA. Hospital-onset Clostridium difficile infection rates in persons with cancer or 

hematopoietic stem cell transplant: a C3IC network report. Infect Control Hosp Epidemiol. 2012 

Nov;33(11):1162-5. Epub 2012 Sep 24. PMCID: 3670420

72. Baden LR, Bensinger W, Angarone M, Casper C, Dubberke ER, Freifeld AG, Garzon R, Greene JN, 

Greer JP, Ito JI, Karp JE, Kaul DR, King E, Mackler E, Marr KA, Montoya JG, Morris-Engemann A, 

Pappas PG, Rolston K, Segal B, Seo SK, Swaminathan S, Naganuma M, Shead DA. Prevention and 

treatment of cancer-related infections. J Natl Compr Canc Netw. 2012 Nov 1;10(11):1412-45. PMCID: 

Not applicable

73. Westblade LF, Chamberland RR, Collins R, Dubberke ER, Dunne WM, Burnham CD. Development 

and evaluation of a novel, semi-automated Clostridium difficile typing platform. J Clin Microbiol. 2012 

Nov 21. [Epub ahead of print]. PMCID: 3553927

74. Hink T, Burnham CD, Dubberke ER. A systematic evaluation of methods to optimize culture-based 

recovery of Clostridium difficile from stool specimens. Anaerobe. Anaerobe. 2012 Dec 13. Epub 

ahead of print]. PMCID: 4146438

75. Bobo LD, El Feghaly RE, Chen YS, Dubberke ER, Han Z, Baker A, Li J, Burnham CA, Haslam DB.

MK2 Kinase Contributes to Clostridium difficile-Associated Inflammation. Infect Immun. 2012 Dec 21. 

[Epub ahead of print]. PMCID: 3584893

76. Dubberke ER, Burdette SD; AST Infectious Diseases Community of Practice. Clostridium difficile 

infections in solid organ transplantation. Am J Transplant. 2013 Mar;13 Suppl 4:42-9. PMCID: Not 

applicable

77. Micek ST, Schramm G, Morrow L, Frazee E, Personett H, Doherty JA, Hampton N, Hoban A, Lieu A, 

McKenzie M, Dubberke ER, Kollef MH. Clostridium difficile infection: a multicenter study of 

epidemiology and outcomes in mechanically ventilated patients. Crit Care Med. 2013 Aug;41(8):1968-

75. PMCID: Not applicable
Curriculum Vitae

Erik Richard Dubberke, MD, MSPH

19

78. Honda H, Yamazaki A, Sato Y, Dubberke ER. Incidence and mortality associated with Clostridium 

difficile infection at a Japanese tertiary care center. Anaerobe. 2013 Nov 1. doi:pii: S1075-

9964(13)00171-6. 10.1016/j.anaerobe.2013.10.004. [Epub ahead of print]. PMCID: Not applicable

79. Honda H, Dubberke ER. The Changing Epidemiology of Clostridium difficile Infection. Curr Opin 

Gastroentero. 2014 Jan;30(1):54-62. PMCID: Not applicable

80. Zilberberg MD, Reske KA, Olsen MA, Yan Y, Dubberke ER. Development and Validation of a 

Recurrent Clostridium difficile Infection Risk Prediction Model. J Hosp Medicine. 2014 Apr 4. doi: 

10.1002/jhm.2189. [Epub ahead of print]. PMCID: Not applicable

81. Yokoe DS, Anderson DJ, Berenholtz SM, Calfee DP, Dubberke ER, Ellingson K, Gerding DN, Haas 

J, Kaye KS, Klompas M, Lo E, Marschall J, Mermel LA, Nicolle L, Salgado C, Bryant K, Classen D, 

Crist K, Foster N, Humphreys E, Padberg J, Podgorny K, Vanamringe M, Weaver T, Wise R, 

Maragakis LL. Introduction to "A Compendium of Strategies To Prevent Healthcare-Associated 

Infections in Acute Care Hospitals: 2014 updates". Infect Control Hosp Epidemiol. 2014 

May;35(5):455-9. doi: 10.1086/675819. PMCID: Not applicable

82. Alasmari F, Seiler SM, Hink T, Burnham CD, Dubberke ER. Prevalence and risk factors for 

asymptomatic Clostridium difficile carriage. Clin Infect Dis. 2014 Jul 15; 59(2)216-22. PMCID: 

PMC4133563

83. Dubberke ER, Carling P, Carrico R, Donskey CJ, Loo VG, McDonald LC, Maragakis LL, Sandora TJ, 

Weber DJ, Yokoe DS, Gerding DN. Strategies to prevent Clostridium difficile infections in acute care 

hospitals: 2014 Update. Infect Control Hosp Epidemiol. 2014 Jun;35(6):628-45. doi: 10.1086/676023

84. Zilberberg M, Reske K, Olsen M, Yan Y, Dubberke E. Risk factors for recurrent Clostridium difficile

infection (CDI) hospitalization among hospitalized patients with an initial CDI episode: a retrospective 

cohort. BMC Infect Dis. 2014 Jun 4;14:306. doi: 10.1186/1471-2334-14-306. PMCID: Not applicable

85. Honda H, Dubberke ER. Clostridium difficile infection in solid organ transplant recipients. Curr Opin 

Infect Dis. 2014 Aug;27(4):336-41. doi: 10.1097/QCO.0000000000000075. PMCID: Not applicable

86. Lanzas C, Dubberke ER. Effectiveness of Screening Hospital Admissions to Detect Asymptomatic 

Carriers of Clostridium difficile: A Modeling Evaluation. Infect Control Hosp Epidemiol. 2014 

Aug;35(8):1043-50. doi: 10.1086/677162. Epub 2014 Jun 20. PMCID: pending

87. Gupta SB, Dubberke ER. Overview and changing epidemiology of Clostridium difficile infection. 

Seminars in Colon and Rectal Surgery. 2014; 25: 118-123 PMCID: Not applicable

88. Zhou Y, Burnham CA, Hink T, Chen L, Shaikh N, Wollam A, Sodergren E, Weinstock GM, Tarr PI, 

Dubberke ER. Phenotypic and genotypic analysis of Clostridium difficile isolates: a single center 

study. J Clin Microbiol. 2014 Oct 1. pii: JCM.02115-14. [Epub ahead of print] PMCID: pending

89. Echaiz JF, Veras L, Zervos M, Dubberke E, Johnson L. Hospital roommates and development of 

health care-onset Clostridium difficile infection. Am J Infect Control. 2014 Oct;42(10):1109-11. doi: 

10.1016/j.ajic.2014.06.023.

90. Dubberke ER, Schaefer E, Reske KA, Zilberberg M, Hollenbeak CS, Olsen MA . Attributable Costs of 

Recurrent Clostridium difficile Infections. Infect Control Hosp Epidemiol. Accepted. PMCID: pending.

91. Olsen MA, Yan Y, Reske KA, Zilberberg MD, Dubberke ER. Recurrent Clostridium difficile infection is 

associated with increased mortality. Clin Microbiol Infect. 2015 Feb;21(2):164-70. PMCID: Not 

applicable.

92. Kwon JH, Olsen MA, Dubberke ER. The morbidity, mortality, and costs associated with Clostridium 

difficile infection. Infect Dis Clin North Am. 2015 Mar;29(1):123-34. PMCID: Not applicable.

93. Olsen MA, Yan Y, Reske KA, Zilberberg M, Dubberke ER. Impact of Clostridium difficile recurrence 

on hospital readmissions. Am J Infect Control. 2015 Apr 1;43(4):318-22. PMCID: Not applicable.

94. Saeed MJ, Dubberke ER, Fraser VJ, Olsen MA. Procedure-specific surgical site infection incidence 

varies widely within certain National Healthcare Safety Network surgery groups. Am J Infect Control. 

2015 Mar 26. pii: S0196-6553(15)00108-X. doi: 10.1016/j.ajic.2015.02.012. [Epub ahead of print]. 

PMCID: Not applicable.

95. Saint S, Fowler KE, Krein SL, Ratz D, Flanders SA, Dubberke ER, Greene MT. Clostridium difficile

Infection in the United States: A National Study Assessing Preventive Practices Used and 

Perceptions of Practice Evidence. Infect Control Hosp Epidemiol. 2015 Apr 21:1-3. [Epub ahead of 

print]. PMCID: pending.
Curriculum Vitae

Erik Richard Dubberke, MD, MSPH

20

96. Young-Xu Y,Kuntz JL, Neily J, Mills P, Gerding DN, Dubberke ER, Olsen MA, Kelly CP, Felter

CT,Mahé C. Clostridium difficile Infection among Veterans Health Administration Patients. Infect 

Control Hosp Epidemiol. 2015 Jun 5:1-8. PMCID: Not applicable.

97. Dubberke ER, Reske KA, Seiler S, Hink T, Kwon JH, Burnham CD. Risk Factors for Acquisition and 

Loss of Clostridium difficile Colonization in Hospitalized Patients. Antimicrobial Agents and 

Chemotherapy. 2015 Aug; 59(8):4533-43. PMCID: pending.

98. Morgan DJ, Leekha S, Croft L, Burnham CA, Johnson JK, Pineles L, Harris AD, Dubberke ER. The 

Importance of Colonization with Clostridium difficile on Infection and Transmission. Curr Infect Dis 

Rep. 2015 Sep;17(9):499. PMCID: Not applicable.

99. Gonzalez MD, Wallace MA, Hink T, Dubberke ER, Burnham CD. Evaluation of 

ceftolozane/tazobactam activity against phylogenetically diverse Clostridium difficile strains.

Antimicrob Agents Chemother. 2015 Nov;59(11):7084-5. [Epub ahead of print] PMCID: Not 

applicable.

100. Kwon JH, Bommarito KM, Reske KA, Seiler SM, Hink T, Babcock H, Kollef MH, Fraser VJ, Burnham 

CD, Dubberke ER. Randomized Controlled Trial to Determine the Impact of Probiotic Administration 

on Colonization with Multidrug-Resistant Organisms in Critically Ill Patients. Infection Control and

Hospital Epidemiology. 2015 Dec;36(12):1451-4.

101. Dubberke ER, Burnham CD. Diagnosis of Clostridium difficile Infection: Treat the Patient, Not the 

Test. JAMA Internal Medicine. 2015 Nov;175(11):1801-2.

102. Young JA, Logan BR, Wu J, Wingard JR, Weisdorf DJ, Mudrick C, Knust K, Horowitz MM, Confer DL, 

Dubberke ER, Pergam SA, Marty FM, Strasfeld LM, Brown JW, Langston AA, Schuster MG, Kaul 

DR, Martin SI, Anasetti C; Blood and Marrow Transplant Clinical Trials Network Trial 0201. Infections 

after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors. Biol 

Blood Marrow Transplant. 2016 Feb;22(2):359-70.

103. Orenstein R, Dubberke ER, Hardi R, Ray A, Mullane K, Pardi DS, Ramesh MS; PUNCH CD 

Investigators. Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium 

difficile Infection: Results of the PUNCH CD Study. Clin Infect Dis. 2016 Mar 1;62(5):596-602.

104. Burnham CA, Dubberke ER, Kociolek LK, Polage CR, Riley TV. Clostridium difficile-Diagnostic and 

Clinical Challenges. Clin Chem. 2016 Feb;62(2):310-4.

105. Dubberke ER, Olsen MA, Stwalley D, Kelly CP, Gerding DN, Young-Xu Y, Mahé C. Identification of 

Medicare Recipients at Highest Risk for Clostridium difficile Infection in the US by Population 

Attributable Risk Analysis. PLoS One. 2016 Feb 9;11(2):e0146822.

106. Durham DP, Olsen MA, Dubberke ER, Galvani AP, Townsend JP. Quantifying Transmission of 

Clostridium difficile within and outside Healthcare Settings. Emerg Infect Dis. 2016 Apr;22(4):608-16.

107. Olsen MA, Young-Xu Y, Stwalley D, Kelly CP, Gerding DN, Saeed MJ, Mahe C, Dubberke ER. The 

Burden of Clostridium difficile Infection: Estimates of the Incidence of CDI from U.S. Administrative 

Databases. BMC Infectious Diseases. 2016 Apr 22; 16:177. 

108. Dubberke ER, Mullane KM, Gerding DN, Lee CH, Louie TJ, Guthertz H, Jones C. Clearance of 

Vancomycin-Resistant Enterococcus Concomitant with Administration of a Microbiota-based Drug 

Targeted at Recurrent Clostridium difficile Infection. Open Forum Infect Dis. 2016. doi: 

10.1093/ofid/ofw133. First published online: June 19, 2016

109. Desai K, Supta S, Dubberke ER, Prabhu VS, Browne C, Mast TC. Epidemiological and economic 

burden of Clostridium difficile in the United States: estimates from a modeling approach. BMC 

Infectious Diseases. 2016 Jun 18; 16:303. 

110. Gupta SB, Mehta V, Dubberke ER, Zhao X, Dorr MB, Guris D, Molrine D, Leney M, Miller M, Dupin 

M, Mast TC. Antibodies to Toxin B Are Protective Against Clostridium difficile Infection Recurrence. 

Clin Infect Dis. 2016 Sep 15:63(6):730-4. 

111. Baden LR, Swaminathan S, Angarone M, Blouin G, Camins BC, Casper C, Cooper B, Dubberke ER, 

Engemann AM, Freifeld AG, Greene JN, Ito JI, Kaul DR, Lustberg ME, Montoya JG, Rolston K, 

Satyanarayana G, Segal B, Seo SK, Shoham S, Taplitz R, Topal J, Wilson JW, Hoffman KG, Smith 

C. Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice 

Guidelines in Oncology. J Natl Compr Canc Netw. 2016 Jul;14(7):882-913.

112. Goldsmith SR, Slade M, DiPersio JF, Westervelt P, Lawrence SJ, Uy GL, Abboud CN, Vij R, 

Schroeder MA, Fehniger TA, Dubberke ER, Trinkaus K, Romee R. Cytomegalovirus viremia, 
Curriculum Vitae

Erik Richard Dubberke, MD, MSPH

21

disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell 

transplantation with post-transplant cyclophosphamide. Haematologica. 2016 Jul 21. pii: 

haematol.2016.149880.

113. Kwon JH, Lanzas C, Reske KA, Hink T, Seiler SM, Bommarito KM, Burnham CD, Dubberke ER. An 

Evaluation of Food as a Potential Source for Clostridium difficile Acquisition in Hospitalized Patients. 

Infect Control Hosp Epidemiol. 2016 Dec;37(12):1401-1407.

114. Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, Cornely OA, Rahav G, Bouza E, Lee 

C, Jenkin G, Jensen W, Kim YS, Yoshida J, Gabryelski L, Pedley A, Eves K, Tipping R, Guris D, 

Kartsonis N, Dorr MB; MODIFY I and MODIFY II Investigators. Bezlotoxumab for Prevention of 

Recurrent Clostridium difficile Infection. N Engl J Med. 2017 Jan 26;376(4):305-317.

115. Kwon JH, Reske KA, Hink T, Burnham CA, Dubberke ER. Evaluation of Correlation between Pretest 

Probability for Clostridium difficile Infection and Clostridium difficile Enzyme Immunoassay Results. J 

Clin Microbiol. 2017 Feb;55(2):596-605. doi: 10.1128/JCM.02126-16.

116. Slade M, Goldsmith S, Romee R, DiPersio JF, Dubberke ER, Westervelt P, Uy GL, Lawrence SJ. 

Epidemiology of infections following haploidentical peripheral blood hematopoietic cell 

transplantation. Transpl Infect Dis. 2017 Feb;19(1).

117. Dubberke ER, Reske KA, Olsen MA, Bommarito K, Seiler S, Silveira FP, Chiller TM, Dipersio J, 

Fraser VJ. Risk for Clostridium difficile Infection after Allogeneic Hematopoietic Cell Transplant 

Remains Elevated in the Postengraftment Period. Transplantation Direct. 2017. Transplant Direct. 

2017 Mar 17;3(4):e145.

118. Schuster MG, Cleveland AA, Dubberke ER, Kauffman CA, Avery RK, Husain S, Paterson DL, 

Silveira FP, Chiller TM, Benedict K, Murphy K, Pappas PG. Infections in Hematopoietic Cell 

Transplant Recipients: Results from The Organ Transplant Infection Project (OTIP), a Multi-Center, 

Prospective, Cohort Study. Open Forum Infect Dis. 2017 Mar 22;4(2)

119. Kwon JH, Burnham CD, Reske KA, Liang SY, Hink T, Wallace MA, Shupe A, Seiler S, Cass C, 

Fraser VJ, Dubberke ER. Assessment of Healthcare Worker Protocol Deviations and SelfContamination During Personal Protective Equipment Donning and Doffing. Infect Control Hosp 

Epidemiol. 2017. Jun 13:1-7

120. Walker T, Ciorba M, Dubberke ER. Reducing Fluoroquinolone Use Is a Key Step in Controlling the 

Burden of Clostridium difficile Infection. Gastroenterology. 2017 Aug;153(2):606-607.

121. Escobar GJ, Baker JM, Kipnis P, Greene JD, Mast TC, Dupta SB, Cossrow N, Mehta V, Liu V, 

Dubberke ER. Prediction of Recurrent Clostridium difficile Infection Using Comprehensive Electronic 

Medical Records in an Integrated Healthcare Delivery System. Infect Control Hosp Epidemiol. 2017 

Aug 24:1-8. doi: 10.1017/ice.2017.176. [Epub ahead of print]

122. Lewis B, Carter R, Ling L, Leiner I, Taur Y, Kamboj M, Dubberke E, Xavier J, Pamer E. Pathogenicity 

locus, core genome and accessory gene contributions to Clostridium difficile virulence. mBio. 2017 

Aug 8;8(4). pii: e00885-17. doi: 10.1128/mBio.00885-17.

123. Prabhu VS, Cornely OA, Golan Y, Dubberke ER, Heimann SM, Hanson ME, Liao J, Pedley A, Dorr 

MB, Marcella S. Thirty-day Readmissions in Hospitalized Patients who Received Bezlotoxumab with 

Antibacterial Drug Treatment for Clostridium difficile Infection. Clin Infect Dis. 2017 Oct 1; (65)7:1218-

1221

124. Kwon JH, Reske KA, Hink T, Seiler SM, Wallace MA, Bommarito KM, Burnham CD, Dubberke ER. 

An Evaluation of the Prevalence of Vancomycin-Resistant Enterococci (VRE) and MethicillinResistant Staphylococcus aureus (MRSA) in Hospital Food. Infect Control Hosp Epidemiol. 2017 

Nov;38(11):1373-1375

125. O'Halloran JA, Franklin A, Lainhart W, Burnham CA, Powderly W, Dubberke ER. Pitfalls Associated 

With the Use of Molecular Diagnostic Panels in the Diagnosis of Cryptococcal Meningitis. Open 

Forum Infect Dis. 2017 Nov 3;4(4)

126. Prabhu VS, Dubberke ER, Dorr MB, Elbasha E, Cossrow N, Jiang Y, Marcella S. Cost-effectiveness 

of Bezlotoxumab Compared with Placebo for the Prevention of Recurrent Clostridium difficile

Infection. Clin Infect Dis. 2018 Jan 18;66(3):355-362

127. Mejia-Chew C, Dubberke ER. Clostridium difficile control measures: current and future methods for 

prevention. Expert Rev Anti Infect Ther. 2018 Feb;16(2):121-131.
Curriculum Vitae

Erik Richard Dubberke, MD, MSPH

22

128. Dubberke ER, Reske KA, Olsen MA, Bommarito K, Cleveland AA, Silveira FP, Schuster MG, 

Kauffman CA, Avery RK, Pappas PG, Chiller TM. Epidemiology and Outcomes of Clostridium difficile 

Infection in Allogeneic Hematopoietic Cell and Lung Transplant Recipients. Transpl Infect Dis. 2018 

Feb 10.

129. McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, 

Gould CV, Kelly C, Loo V, Shaklee Sammons J, Sandora TJ, Wilcox MH. Clinical Practice Guidelines 

for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases 

Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect 

Dis. 2018 Mar 19;66(7):987-994

130. Mullane K, Winston DJ, Nooka A, Morris MI, Stiff P, Dugan MJ, Holland H, Gregg K, Adachi JA, 

Pergam SA, Alexander BD, Dubberke ER, Broyde N, Sears PS. A Randomized, Placebo-Controlled 

Trial of Fidaxomicin for Prophylaxis of Clostridium difficile Associated Diarrhea in Adults undergoing 

Hematopoietic Stem Cell Transplantation. Clin Infect Dis. 2018 June 9

131. Avery RK, Silveira FP, Benedict K, Cleveland AA, Kauffman CA, Schuster MG, Dubberke ER, 

Husain S, Paterson DL, Chiller T, Pappas P. Cytomegalovirus infections in lung and hematopoietic 

cell transplant recipients in the Organ Transplant Infection Prevention and Detection Study: A multiyear, multicenter prospective cohort study. Transpl Infect Dis. 2018 Jun;20(3):e12877.

132. Gerding DN, Kelly CP, Rahav G, Lee C, Dubberke ER, Kumar PN, Yacyshyn B, Kao D, Eves K, 

Ellison MC, Hanson ME, Guris D, Dorr MB. Bezlotoxumab for Prevention of Recurrent Clostridium 

difficile Infection in Patients at Increased Risk for Recurrence. Clin Infect Dis. 2018 Aug 16;67(5):649-

656.

133. Yarbrough ML, Kwon JH, Wallace MA, Hink T, Shupe A, Fraser VJ, Dubberke ER, Burnham CA. 

Frequency of Instrument, Environment, and Laboratory Technologist Contamination during Routine 

Diagnostic Testing of Infectious Specimens. J Clin Microbiol. 2018 May 25;56(6)

134. Dubberke ER, Lee CH, Orenstein R, Khanna S, Hecht G, Gerding DN. Results From a Randomized, 

Placebo-Controlled Clinical Trial of a RBX2660-A Microbiota-Based Drug for the Prevention of 

Recurrent Clostridium difficile Infection. Clin Infect Dis. 2018 Sep 28;67(8):1198-1204.

135. Olsen MA, Stwalley D, Demont C, Dubberke ER. Increasing Age Has Limited Impact on Risk of 

Clostridium difficile Infection in an Elderly Population. Open Forum Infect Dis. 2018 Jul 

19;5(7):ofy160.

136. Dubberke ER, Blount K, Gerding DN. Reply to Million et al. Clin Infect Dis. 2018 Nov 13;67(11):1799-

1800

137. Durkin MJ, Keller M, Butler AM, Kwon JH, Dubberke ER, Miller AC, Polgreen PM, Olsen MA. An 

Assessment of Inappropriate Antibiotic Use and Guideline Adherence for Uncomplicated Urinary 

Tract Infections. Open Forum Infect Dis. 2018 Aug 10;5(9):ofy198

138. Dubberke ER, Reske KA, Hink T, Kwon JH, Cass C, Bongu J, Burnham CD, Henderson JP. 

Clostridium difficile colonization among patients with clinically significant diarrhea and no identifiable 

cause of diarrhea. Infect Control Hosp Epidemiol. 2018 Nov;39(11):1330-1333

139. Olsen MA, Stwalley D, Demont C, Dubberke ER. Clostridium difficile infection increases acute and 

chronic morbidity and mortality. Infect Control Hosp Epidemiol. 2018 Nov 9:1-7.

140. Ma J, Dubberke ER. Current management of Clostridioides (Clostridium) difficile infection in adults: a 

summary of recommendations from the 2017 IDSA/SHEA clinical practice guideline. Pol Arch Intern 

Med. 2018 Nov 20.

141. Basu A, Prabhu VS, Dorr MB, Golan Y, Dubberke ER, Cornely OA, Heimann SM, Pedley A, Xu R, 

Hanson ME, Marcella S. Bezlotoxumab Is Associated With a Reduction in Cumulative Inpatient-Days: 

Analysis of the Hospitalization Data From the MODIFY I and II Clinical Trials. Open Forum Infect Dis. 

2018 Nov 15;5(11):ofy218.

142. Bulow C, Langdon A, Hink T, Wallace M, Reske KA, Patel S, Sun X, Seiler S, Jones S, Kwon JH, 

Burnham CA, Dantas G, Dubberke ER. Impact of Amoxicillin-Clavulanate followed by Autologous 

Fecal Microbiota Transplantation on Fecal Microbiome Structure and Metabolic Potential. mSphere. 

2018 Nov 21;3(6)

143. Kato H, Senoh M, Honda H, Fukuda T, Tagashira Y, Horiuchi H, Chiba H, Suzuki D, Hosokawa N, 

Kitazono H, Norisue Y, Kume H, Mori N, Morikawa H, Kashiwagura S, Higuchi A, Kato H, Nakamura 

M, Ishiguro S, Morita S, Ishikawa H, Watanabe T, Kojima K, Yokomaku I, Bando T, Toimoto K, 
Curriculum Vitae

Erik Richard Dubberke, MD, MSPH

23

Moriya K, Kasahara K, Kitada S, Ogawa J, Saito H, Tominaga H, Shimizu Y, Masumoto F, Tadera K, 

Yoshida J, Kikuchi T, Yoshikawa I, Watanabe T, Honda M, Yokote K, Toyokawa T, Miyazato H, 

Nakama M, Mahe C, Reske K, Olsen MA, Dubberke ER. Clostridioides (Clostridium) difficile infection 

burden in Japan: A multicenter prospective study. Anaerobe. 2019 Mar 12. pii: S1075-

9964(19)30046-0. doi: 10.1016/j.anaerobe.2019.03.007. [Epub ahead of print]

144. Pande A, Dubberke ER. Cytomegalovirus Infections of the Stem Cell Transplant Recipient and 

Hematologic Malignancy Patient. Infect Dis Clin North Am. 2019 Jun;33(2):485-500.

145. Mullane KM, Dubberke ER; AST ID Community of Practice. Management of Clostridioides (formerly 

Clostridium) difficile infection (CDI) in solid organ transplant recipients: Guidelines from the American 

Society of Transplantation Community of Practice. Clin Transplant. 2019 Apr 19:e13564. doi: 

10.1111/ctr.13564. [Epub ahead of print]

146. Kutty PK, Beekmann SE, Sinkowitz-Cochran RL, Dubberke ER, Kuhar DT, McDonald LC, Polgreen 

PM. A national survey of testing and management of asymptomatic carriage of C. difficile. Infect 

Control Hosp Epidemiol. 2019 Jul;40(7):801-803. doi: 10.1017/ice.2019.109. Epub 2019 May 20.

147. Wilcox MH, Rahav G, Dubberke ER, Gabryelski L, Davies K, Berry C, Eves K, Ellison MC, Guris D, 

Dorr MB. Influence of Diagnostic Method on Outcomes in Phase 3 Clinical Trials of Bezlotoxumab for 

the Prevention of Recurrent Clostridioides difficile Infection: A Post Hoc Analysis of MODIFY I/II. 

Open Forum Infect Dis. 2019 Aug 1;6(8). pii: ofz293. doi: 10.1093/ofid/ofz293.

148. Robinson JI, Weir WH, Crowley JR, Hink T, Reske KA, Kwon JH, Burnham CD, Dubberke ER, 

Mucha PJ, Henderson JP. Metabolomic networks connect host-microbiome processes to human 

Clostridioides difficile infections. J Clin Invest. 2019 Aug 12;130. pii: 126905. doi: 10.1172/JCI126905. 

eCollection 2019 Aug 12.

Books and Chapters

1. Dubberke ER, Cabellon MCL. The Washington Manuel Infectious Diseases Subspecialty Consult. 1

st

ed. Lippincott Williams and Wilkins. 2005. Chapter, Febrile Syndromes

2. Dubberke ER. The Washington Manuel Infectious Diseases Subspecialty Consult. 1

st ed. Lippincott 

Williams and Wilkins. 2005. Chapter, Bacteremia and Sepsis

3. Dubberke ER. The Washington Manuel Infectious Diseases Subspecialty Consult. 1

st ed. Lippincott 

Williams and Wilkins. 2005. Chapter, Oncologic Infections

4. Dubberke ER. The Washington Manuel Infectious Diseases Subspecialty Consult. 1

st ed. Lippincott 

Williams and Wilkins. 2005. Chapter, Bone Marrow Transplant Infections

5. Dubberke ER. The Washington Manuel Infectious Diseases Subspecialty Consult. 1

st ed. Lippincott 

Williams and Wilkins. 2005. Chapter, Solid Organ Transplant Infections

6. Dubberke ER. The Washington Manuel Infectious Diseases Subspecialty Consult. 1

st ed. Lippincott 

Williams and Wilkins. 2005. Chapter, Protozoa

7. Dubberke ER. The Washington Manuel Infectious Diseases Subspecialty Consult. 1

st ed. Lippincott 

Williams and Wilkins. 2005. Chapter, Travel Medicine

8. Dubberke ER, Fraser VJ. Blueprints in Infectious Diseases. Blackwell Publishers. 2006. Chapter.

Prevention of Infection

9. Dubberke ER. Infectious Diseases in Emergency Medicine. 1

st ed. Cambridge University Press. 2008. 

Chapter, Infections in Oncology Patients

10. Faller B. Dubberke ER. The Washington Manual: General Internal Medicine Consult. 2nd ed. Lippincott 

Williams and Wilkins. 2009. Chapter, Neutropenic Fever

11. Dubberke ER, Brennan D. Suki and Masry’s Therapy of Renal Diseases and Related Disorders. 4

th ed. 

Springer. 2010. Chapter, Infectious Complications in Renal Transplant Recipients

12. Bobo LD, Dubberke ER. Washington Manual of Critical Care. 2

nd ed. Lippincott Williams & Wilkins. 

2011. Chapter, Clostridium difficile and Other Infectious Causes of Diarrhea

13. Dubberke ER, Donskey C. Contemporary Diagnosis and Management of Clostridium difficile Infection. 

Handbooks in Health Care Company. 2012

14. Ward S, Dubberke ER. Transplant Infections. ESun Technologies, LLC. 2012. Chapter, Clostridium 

difficile

15. Han Z. Dubberke ER. The Washington Manual: Infectious Diseases Subspecialty Consult. 2nd ed. . 

Lippincott Williams and Wilkins. 2013, Chapter Infections of the Gastrointestinal and Hepatobiliary Tract
Curriculum Vitae

Erik Richard Dubberke, MD, MSPH

24

16. Blanco-Guzman. MO, Dubberke ER. The Washington Manual: General Internal Medicine Consult. 3rd

ed. Lippincott Williams and Wilkins. 2017. Chapter, Neutropenic Fever

17. Kwon JH, Dubberke ER. Practical Handbook for Healthcare Epidemiology. 4

th ed. Cambridge 

University Press. 2017. Chapter, Clostridium difficile Infection

18. Nazinitski A. Dubberke ER. Infectious Diseases in Emergency Medicine. 2

nd ed. Cambridge University 

Press. 2018. Chapter, Infections in Oncology Patients
EXHIBIT B
Erik Dubberke, list of cases testified, 2015-2019

Case Law Firm Type of 

Case

Side Year 

testified

Corso v 

Bormes

Hepler 

Broom Malpractice Defendant 2015

Sams v 

Mercy

Haden 

Cowherd 

Bullock Malpractice Defendant 2016

Rausch v 

SAMC

Sandber 

Phoenix 

and von 

Gontard Malpractice Defendant 2016

Hunt v 

Jenkins

Haden 

Cowherd 

Bullock Malpractice Defendant 2017

Krawetzki 

v Osborn

Jackson 

and 

Campbell Malpractice Defendant 2018

Gust v 

Rush

Swanson, 

Martin and 

Bell Malpractice Defendant 2019

Cameron 

v Mobile 

infirmary

Helmsing 

Leach Malpractice Defendant 2019

Stallworth

Marsh 

Rickard 

Bryan Malpractice Plaintiff 2019

Harris v 

Lange

Sandber 

Phoenix 

and von 

Gontard Malpractice Defendant 2019

Herman v 

Williams

Hodgkin 

Street 

Mepham Malpractice Defendant 2019
EXHIBIT 2
INSURANCE SERVICES OFFICE, INC. 545 WASHINGTON BOULEVARD JERSEY CITY, NJ 07310-1686

WWW.ISO.COM © ISO Properties, Inc., 2006 Page 1 of 3 

FORMS - FILED JULY 6, 2006

FROM: LARRY PODOSHEN, SENIOR ANALYST 

 COMMERCIAL PROPERTY LI-CF-2006-175

NEW ENDORSEMENTS FILED TO ADDRESS EXCLUSION OF 

LOSS DUE TO VIRUS OR BACTERIA 

This circular announces the submission of forms filings to address exclusion of loss 

due to disease-causing agents such as viruses and bacteria. 

BACKGROUND 

Commercial Property policies currently contain a pollution exclusion that encompasses 

contamination (in fact, uses the term contaminant in addition to other terminology). Although the 

pollution exclusion addresses contamination broadly, viral and bacterial contamination are specific 

types that appear to warrant particular attention at this point in time. 

ISO ACTION 

We have submitted forms filing CF-2006-OVBEF in all ISO jurisdictions and recommended the 

filing to the independent bureaus in other jurisdictions. This filing introduces new endorsement 

CP 01 40 07 06 - Exclusion Of Loss Due To Virus Or Bacteria, which states that there is no coverage 

for loss or damage caused by or resulting from any virus, bacterium or other microorganism 

that induces or is capable of inducing physical distress, illness or disease. 

Note: In Alaska, District of Columbia, Louisiana*, New York and Puerto Rico, we have submitted 

a different version of this filing, containing new endorsement CP 01 75 07 06 in place of CP 01 40. 

The difference relates to lack of implementation of the mold exclusion that was implemented in 

other jurisdictions under a previous multistate filing. 

Both versions of CF-2006-OVBEF are attached to this circular. 

* In Louisiana, the filing was submitted as a recommendation to the Property Insurance Association 

of Louisiana (PIAL), the independent bureau with jurisdiction for submission of property filings. 

PROPOSED EFFECTIVE DATE 

Filing CF-2006-OVBEF was submitted with a proposed effective date of January 1, 2007, in 

accordance with the applicable effective date rule of application in each state, with the exception of 

various states for which the insurer establishes its own effective date. 

Upon approval, we will announce the actual effective date and state-specific rule of effective date 

application for each state. 
LI-CF-2006-175 

© ISO Properties, Inc., 2006 Page 2 of 3

RATING SOFTWARE IMPACT 

New attributes being introduced with this revision: 

• A new form is being introduced. 

CAUTION 

This filing has not yet been approved. If you print your own forms, do not go beyond the proof stage 

until we announce approval in a subsequent circular. 

RELATED RULES REVISION 

We are announcing in a separate circular the filing of a corresponding rules revision. Please refer to 

the Reference(s) block for identification of that circular. 

REFERENCE(S) 

LI-CF-2006-176 (7/6/06) - New Additional Rule Filed To Address Exclusion Of Loss Due To Virus 

Or Bacteria 

ATTACHMENT(S)

• Multistate Forms Filing CF-2006-OVBEF 

• State-specific version of Forms Filing CF-2006-OVBEF (Alaska, District of Columbia, 

Louisiana, New York, Puerto Rico) 

We are sending these attachments only to recipients who asked to be put on the mailing list for 

attachments. If you need the attachments for this circular, contact your company’s circular 

coordinator. 

PERSON(S) TO CONTACT 

If you have any questions concerning: 

• the content of this circular, please contact: 

Larry Podoshen 

Senior Analyst 

Commercial Property 

(201) 469-2597 Fax: (201) 748-1637 

comfal@iso.com

lpodoshen@iso.com

 or 

Loretta Newman, CPCU 

Manager 

Commercial Property 

(201) 469-2582 Fax: (201) 748-1873 

comfal@iso.com

lnewman@iso.com
LI-CF-2006-175 

© ISO Properties, Inc., 2006 Page 3 of 3

• the mailing or distribution of this circular, please contact our Customer Service Division: 

E-mail: info@iso.com

Fax: 201-748-1472 

Phone: 800-888-4476 

World Wide Web: http://www.iso.com

Write: See address on page 1 

• products or services, please call or e-mail ISO Customer Service, or call your ISO 

representative. 

Callers outside the United States may contact us using our global toll-free number (International 

Access Code + 800 48977489) or by e-mail at info.global@iso.com. For information on all ISO 

products, visit us at http://www.iso.com. 
© ISO Properties, Inc., 2006 Edition 11-03

IMPORTANT NOTICE FOR USERS OF 

ISO PRODUCTS AND SERVICES

Please make sure that your company has authorized your use of this product and has complied with the 

requirements applicable in the jurisdiction where you plan to use it.

We distribute both state-specific and multi-state products and services. We do not distribute all the multi-state 

products and services for use in every jurisdiction due to corporate policy, regulatory preference, or variations or 

lack of clarity in state laws. 

We provide participating insurers with information concerning the jurisdictions for which our products and services 

are distributed. Even in those jurisdictions, each insurer must determine what filing requirements, if any, apply 

and whether those requirements have been satisfied. 

Now, as in the past, all of our products and services are advisory, and are made available for optional use by 

participating insurers as a matter of individual choice. Your company must decide for itself which, if any, ISO 

products or services are needed or useful to its operation and how those selected for use should be applied. We 

urge that you be guided by the advice of your attorneys on the legal requirements. 

Copyright Explanation 

 The material distributed by Insurance Services Office, Inc. is copyrighted. All 

rights reserved. Possession of these pages does not confer the right to print, 

reprint, publish, copy, sell, file, or use same in any manner without the 

written permission of the copyright owner. Permission is hereby granted to 

members, subscribers, and service purchasers to reprint, copy, or otherwise 

use the enclosed material for purposes of their own business use relating to 

that territory or line or kind of insurance, or subdivision thereof, for which 

they participate, provided that: 

 A. where ISO copyrighted material is reprinted, copied, or otherwise used 

as a whole, it must reflect the copyright notice actually shown on such 

material. 

 B. where ISO copyrighted material is reprinted, copied, or otherwise used 

in part, the following credit legend must appear at the bottom of each 

page so used: 

 Includes copyrighted material of Insurance Services Office, Inc., with its 

permission. 
© ISO Properties, Inc., 2006 

COMMERCIAL FIRE AND ALLIED LINES 

FORMS FILING CF-2006-OVBEF 

Amendatory Endorsement - 

Exclusion Of Loss Due To Virus Or 

Bacteria 

About This Filing 

This filing addresses exclusion of loss due to disease-causing agents such as 

viruses and bacteria. 

New Form 

We are introducing: 

♦ Endorsement CP 01 40 07 06 - Exclusion Of Loss Due To Virus Or Bacteria 

Related Filing(s) 

Rules Filing CF-2006- OVBER 

Introduction 

The current pollution exclusion in property policies encompasses contamination 

(in fact, uses the term contaminant in addition to other terminology). Although 

the pollution exclusion addresses contamination broadly, viral and bacterial 

contamination are specific types that appear to warrant particular attention at this 

point in time. 

An example of bacterial contamination of a product is the growth of listeria 

bacteria in milk. In this example, bacteria develop and multiply due in part to 

inherent qualities in the property itself. Some other examples of viral and 

bacterial contaminants are rotavirus, SARS, influenza (such as avian flu), 

legionella and anthrax. The universe of disease-causing organisms is always in 

evolution. 

Disease-causing agents may render a product impure (change its quality or 

substance), or enable the spread of disease by their presence on interior building 

surfaces or the surfaces of personal property. When disease-causing viral or 

bacterial contamination occurs, potential claims involve the cost of replacement 

of property (for example, the milk), cost of decontamination (for example, 

interior building surfaces), and business interruption (time element) losses. 
COMMERCIAL FIRE AND ALLIED LINES 

FORMS FILING CF-2006- OVBEF Page 2

© ISO Properties, Inc., 2006 

Current Concerns 

Although building and personal property could arguably become contaminated 

(often temporarily) by such viruses and bacteria, the nature of the property itself 

would have a bearing on whether there is actual property damage. An allegation 

of property damage may be a point of disagreement in a particular case. In 

addition, pollution exclusions are at times narrowly applied by certain courts. In 

recent years, ISO has filed exclusions to address specific exposures relating to 

contaminating or harmful substances. Examples are the mold exclusion in 

property and liability policies and the liability exclusion addressing silica dust. 

Such exclusions enable elaboration of the specific exposure and thereby can 

reduce the likelihood of claim disputes and litigation. 

While property policies have not been a source of recovery for losses involving 

contamination by disease-causing agents, the specter of pandemic or hitherto 

unorthodox transmission of infectious material raises the concern that insurers 

employing such policies may face claims in which there are efforts to expand 

coverage and to create sources of recovery for such losses, contrary to policy 

intent. 

In light of these concerns, we are presenting an exclusion relating to 

contamination by disease-causing viruses or bacteria or other disease-causing 

microorganisms. 

Features Of New Amendatory Endorsement 

The amendatory endorsement presented in this filing states that there is no 

coverage for loss or damage caused by or resulting from any virus, 

bacterium or other microorganism that induces or is capable of inducing 

physical distress, illness or disease. The exclusion (which is set forth in 

Paragraph B of the endorsement) applies to property damage, time element and 

all other coverages; introductory Paragraph A prominently makes that point. 

Paragraphs C and D serve to avoid overlap with other exclusions, and Paragraph 

E emphasizes that other policy exclusions may still apply. 

Copyright Explanation 

The material distributed by Insurance Services Office, Inc. is copyrighted. All 

rights reserved. Possession of these pages does not confer the right to print, 

reprint, publish, copy, sell, file or use same in any manner without the written 

permission of the copyright owner. 
COMMERCIAL FIRE AND ALLIED LINES 

FORMS FILING CF-2006- OVBEF Page 3

© ISO Properties, Inc., 2006 

Important Note 

Insurance Services Office, Inc. (ISO) makes available advisory services to 

property/casualty insurers. ISO has no adherence requirements. ISO policy forms 

and explanatory materials are intended solely for the information and use of 

ISO's participating insurers and their representatives, and insurance regulators. 

Neither ISO's general explanations of policy intent nor opinions expressed by 

ISO's staff necessarily reflect every insurer's view or control any insurer's 

determination of coverage for a specific claim. ISO does not intercede in 

coverage disputes arising from insurance policies. If there is any conflict between 

a form and any other part of the attached material, the provisions of the form 

apply. 
COMMERCIAL PROPERTY

CP 01 40 07 06

THIS ENDORSEMENT CHANGES THE POLICY. PLEASE READ IT CAREFULLY. 

CP 01 40 07 06 © ISO Properties, Inc., 2006 Page 1 of 1 

N

E

W

 EXCLUSION OF LOSS DUE TO VIRUS OR BACTERIA 

This endorsement modifies insurance provided under the following: 

COMMERCIAL PROPERTY COVERAGE PART 

STANDARD PROPERTY POLICY 

A. The exclusion set forth in Paragraph B. applies to 

all coverage under all forms and endorsements 

that comprise this Coverage Part or Policy, including but not limited to forms or endorsements that 

cover property damage to buildings or personal 

property and forms or endorsements that cover 

business income, extra expense or action of civil 

authority. 

B. We will not pay for loss or damage caused by or 

resulting from any virus, bacterium or other microorganism that induces or is capable of inducing 

physical distress, illness or disease. 

 However, this exclusion does not apply to loss or 

damage caused by or resulting from "fungus", wet 

rot or dry rot. Such loss or damage is addressed in 

a separate exclusion in this Coverage Part or Policy. 

C. With respect to any loss or damage subject to the 

exclusion in Paragraph B., such exclusion supersedes any exclusion relating to "pollutants". 

D. The following provisions in this Coverage Part or 

Policy are hereby amended to remove reference 

to bacteria: 

 1. Exclusion of "Fungus", Wet Rot, Dry Rot And 

Bacteria; and 

2. Additional Coverage - Limited Coverage for 

"Fungus", Wet Rot, Dry Rot And Bacteria, including any endorsement increasing the scope 

or amount of coverage. 

E. The terms of the exclusion in Paragraph B., or the 

inapplicability of this exclusion to a particular loss, 

do not serve to create coverage for any loss that 

would otherwise be excluded under this Coverage 

Part or Policy.
© ISO Properties, Inc., 2006 

ALASKA, DISTRICT OF COLUMBIA, LOUISIANA, NEW YORK, PUERTO RICO 

COMMERCIAL FIRE AND ALLIED LINES 

FORMS FILING CF-2006-OVBEF 

Amendatory Endorsement - 

Exclusion Of Loss Due To Virus Or 

Bacteria 

About This Filing 

This filing addresses exclusion of loss due to disease-causing agents such as 

viruses and bacteria. 

New Form 

We are introducing: 

♦ Endorsement CP 01 75 07 06 - Exclusion Of Loss Due To Virus Or Bacteria 

Related Filing(s) 

Rules Filing CF-2006-OVBER 

Introduction 

The current pollution exclusion in property policies encompasses contamination 

(in fact, uses the term contaminant in addition to other terminology). Although 

the pollution exclusion addresses contamination broadly, viral and bacterial 

contamination are specific types that appear to warrant particular attention at this 

point in time. 

An example of bacterial contamination of a product is the growth of listeria 

bacteria in milk. In this example, bacteria develop and multiply due in part to 

inherent qualities in the property itself. Some other examples of viral and 

bacterial contaminants are rotavirus, SARS, influenza (such as avian flu), 

legionella and anthrax. The universe of disease-causing organisms is always in 

evolution. 

Disease-causing agents may render a product impure (change its quality or 

substance), or enable the spread of disease by their presence on interior building 

surfaces or the surfaces of personal property. When disease-causing viral or 

bacterial contamination occurs, potential claims involve the cost of replacement 
COMMERCIAL FIRE AND ALLIED LINES 

FORMS FILING CF-2006-OVBEF Page 2

© ISO Properties, Inc., 2006 

of property (for example, the milk), cost of decontamination (for example, 

interior building surfaces), and business interruption (time element) losses. 

Current Concerns 

Although building and personal property could arguably become contaminated 

(often temporarily) by such viruses and bacteria, the nature of the property itself 

would have a bearing on whether there is actual property damage. An allegation 

of property damage may be a point of disagreement in a particular case. In 

addition, pollution exclusions are at times narrowly applied by certain courts. In 

recent years, ISO has filed exclusions to address specific exposures relating to 

contaminating or harmful substances. Examples are the mold exclusion in 

property and liability policies and the liability exclusion addressing silica dust. 

Such exclusions enable elaboration of the specific exposure and thereby can 

reduce the likelihood of claim disputes and litigation. 

While property policies have not been a source of recovery for losses involving 

contamination by disease-causing agents, the specter of pandemic or hitherto 

unorthodox transmission of infectious material raises the concern that insurers 

employing such policies may face claims in which there are efforts to expand 

coverage and to create sources of recovery for such losses, contrary to policy 

intent. 

In light of these concerns, we are presenting an exclusion relating to 

contamination by disease-causing viruses or bacteria or other disease-causing 

microorganisms. 

Features Of New Amendatory Endorsement 

The amendatory endorsement presented in this filing states that there is no 

coverage for loss or damage caused by or resulting from any virus, 

bacterium or other microorganism that induces or is capable of inducing 

physical distress, illness or disease. The exclusion (which is set forth in 

Paragraph B of the endorsement) applies to property damage, time element and 

all other coverages; introductory Paragraph A prominently makes that point. 

Paragraph C serves to avoid overlap with another exclusion, and Paragraph D 

emphasizes that other policy exclusions may still apply. 

Copyright Explanation 

The material distributed by Insurance Services Office, Inc. is copyrighted. All 

rights reserved. Possession of these pages does not confer the right to print, 

reprint, publish, copy, sell, file or use same in any manner without the written 

permission of the copyright owner. 
COMMERCIAL FIRE AND ALLIED LINES 

FORMS FILING CF-2006-OVBEF Page 3

© ISO Properties, Inc., 2006 

Important Note 

Insurance Services Office, Inc. (ISO) makes available advisory services to 

property/casualty insurers. ISO has no adherence requirements. ISO policy forms 

and explanatory materials are intended solely for the information and use of 

ISO's participating insurers and their representatives, and insurance regulators. 

Neither ISO's general explanations of policy intent nor opinions expressed by 

ISO's staff necessarily reflect every insurer's view or control any insurer's 

determination of coverage for a specific claim. ISO does not intercede in 

coverage disputes arising from insurance policies. If there is any conflict between 

a form and any other part of the attached material, the provisions of the form 

apply. 
COMMERCIAL PROPERTY

CP 01 75 07 06

THIS ENDORSEMENT CHANGES THE POLICY. PLEASE READ IT CAREFULLY. 

CP 01 75 07 06 © ISO Properties, Inc., 2006 Page 1 of 1 

N

E

W

 EXCLUSION OF LOSS DUE TO VIRUS OR BACTERIA 

This endorsement modifies insurance provided under the following: 

COMMERCIAL PROPERTY COVERAGE PART 

STANDARD PROPERTY POLICY 

A. The exclusion set forth in Paragraph B. applies to 

all coverage under all forms and endorsements 

that comprise this Coverage Part or Policy, including but not limited to forms or endorsements that 

cover property damage to buildings or personal 

property and forms or endorsements that cover 

business income, extra expense or action of civil 

authority. 

B. We will not pay for loss or damage caused by or 

resulting from any virus, bacterium or other microorganism that induces or is capable of inducing 

physical distress, illness or disease. 

 However, this exclusion does not apply to loss or 

damage caused by or resulting from fungus. Such 

loss or damage is addressed in a separate exclusion in this Coverage Part or Policy. 

C. With respect to any loss or damage subject to the 

exclusion in Paragraph B., such exclusion supersedes any exclusion relating to "pollutants". 

D. The terms of the exclusion in Paragraph B., or the 

inapplicability of this exclusion to a particular loss, 

do not serve to create coverage for any loss that 

would otherwise be excluded under this Coverage 

Part or Policy.